var title_f5_48_5888="Superficial onychomycosis";
var content_f5_48_5888=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F66643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F66643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White superficial onychomycosis caused by T. mentagrophytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5888=[""].join("\n");
var outline_f5_48_5888=null;
var title_f5_48_5889="Interactive diabetes case 1: Inpatient management in type 1 diabetes";
var content_f5_48_5889=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Interactive diabetes case 1: Inpatient management in type 1 diabetes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5889/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5889/contributors\">",
"     Lloyd Axelrod, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5889/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5889/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5889/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5889/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/48/5889/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     CASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 60-year-old woman with a 48-year history of type 1 diabetes was admitted to the hospital for syncope. The patient had been on a diabetic diet in a nursing home, where she lived because of severe autonomic neuropathy with orthostatic hypotension. The syncope was ultimately attributed to the autonomic neuropathy and treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/35/2613?source=see_link\">",
"     midodrine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    She had been on NPH insulin 15 units and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"     regular insulin",
"    </a>",
"    5 units before breakfast, regular insulin 5 units before dinner and NPH insulin 6 units at bedtime. Her glucose control on this regimen had been satisfactory for her setting, with only occasional insulin reactions. The hemoglobin A1c on admission was 7.8 percent.",
"   </p>",
"   <p>",
"    On the first full hospital day, the 6:30 AM blood glucose level was 101",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.6",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    You advise which of the following?",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hold NPH insulin due to hypoglycemia and cover with sliding scale. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?5/48/5889-a1?source=see_link\">",
"       \"Interactive diabetes case 1: Inpatient management in type 1 diabetes - A1\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Give NPH insulin 15 units and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/45/8922?source=see_link\">",
"       regular insulin",
"      </a>",
"      5 units before breakfast, her usual doses. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?5/48/5889-a2?source=see_link\">",
"       \"Interactive diabetes case 1: Inpatient management in type 1 diabetes - A2\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Give NPH 10 units before breakfast, begin 5 percent dextrose intravenously at 100",
"      <span class=\"nowrap\">",
"       cc/hour",
"      </span>",
"      and keep patient NPO. (See",
"      <a class=\"medical medical_answer\" href=\"UTD.htm?5/48/5889-a3?source=see_link\">",
"       \"Interactive diabetes case 1: Inpatient management in type 1 diabetes - A3\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4108 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-7705E05A5A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5889=[""].join("\n");
var outline_f5_48_5889=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      CASE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?5/48/5889-a1?source=related_link\">",
"      Interactive diabetes case 1: Inpatient management in type 1 diabetes - A1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?5/48/5889-a2?source=related_link\">",
"      Interactive diabetes case 1: Inpatient management in type 1 diabetes - A2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_answer\" href=\"UTD.htm?5/48/5889-a3?source=related_link\">",
"      Interactive diabetes case 1: Inpatient management in type 1 diabetes - A3",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_48_5890="Ectop preg hemoperit Doppl";
var content_f5_48_5890=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57420&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ectopic pregnancy with hemoperitoneum (Doppler color ultrasound)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transvaginal imaging of the adnexa was limited in this patient due to the presence of hemoperitoneum. Color Doppler assisted in identifying the site of ectopic pregnancy (E) in this patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Tejas S Mehta, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5890=[""].join("\n");
var outline_f5_48_5890=null;
var title_f5_48_5891="Herpes simplex - oral";
var content_f5_48_5891=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Herpes simplex virus infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions and vesicular lesions are present in the mouth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5891=[""].join("\n");
var outline_f5_48_5891=null;
var title_f5_48_5892="Hemoglobin C disease";
var content_f5_48_5892=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F61082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F61082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemoglobin C disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 254px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral smear from a patient with homozygous hemoglobin C disease, showing the presence of hemoglobin crystals (blue arrows) within erythrocytes. This phenomenon is most commonly seen when a wet preparation of red cells is allowed to partially dehydrate. Target cells (black arrow) are also present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen A. Landaw, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5892=[""].join("\n");
var outline_f5_48_5892=null;
var title_f5_48_5893="PMLE neck";
var content_f5_48_5893=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Polymorphous light eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Erythematous papules developed on the dorsal hands, forearms, face, neck, and upper chest of this 40-year-old man with a history of sun exposure. The patient's history and symptoms were consistent with polymorphous light eruption.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Shahbaz A Janjua, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5893=[""].join("\n");
var outline_f5_48_5893=null;
var title_f5_48_5894="Transpancreatic precut";
var content_f5_48_5894=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Transpancreatic precut sphincterotomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Martin L Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5894=[""].join("\n");
var outline_f5_48_5894=null;
var title_f5_48_5895="Esmolol: Pediatric drug information";
var content_f5_48_5895=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Esmolol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"    see \"Esmolol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/27/3508?source=see_link\">",
"    see \"Esmolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166884\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Brevibloc",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Brevibloc&reg;;",
"     </li>",
"     <li>",
"      Brevibloc&reg; Premixed",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiarrhythmic Agent, Class II",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta-Adrenergic Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442485\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Must be adjusted to individual response and tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postoperative hypertension: Limited data available; further studies are needed. An open-label trial used the following dosing guidelines to treat postoperative hypertension following cardiac surgery; dose was titrated until blood pressure was &le;90th percentile for age; final dose required was significantly higher in patients with aortic coarctation repair than in patients with repair of other congenital heart defects (Wiest, 1998):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Term neonates: PNA 0-7 days: Initial: 50 mcg/kg/minute; titrate dose by 25-50 mcg/kg/minute every 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Term neonates: PNA 8-28 days: Initial: 75 mcg/kg/minute; titrate dose by 50 mcg/kg/minute every 20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Maximum dose: 1000 mcg/kg/minute; higher doses have not been evaluated",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"      see \"Esmolol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Must be adjusted to individual response and tolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children: I.V.: Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Supraventricular tachycardia (SVT): Some centers have utilized initial doses of 100-500 mcg/kg given over 1 minute followed by a continuous infusion for control of SVT. One electrophysiologic study assessing esmolol-induced beta-blockade (n=20, 2-16 years of age) used an initial dose of 600 mcg/kg over 2 minutes followed by an infusion of 200 mcg/kg/minute; the infusion was titrated upward by 50-100 mcg/kg/minute every 5-10 minutes until a reduction &gt;10% in heart rate or mean blood pressure occurred. Mean dose required: 550 mcg/kg/minute with a range of 300-1000 mcg/kg/minute (Trippel, 1991).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Postoperative hypertension: Loading doses of 500 mcg/kg/minute over 1 minute followed by a continuous infusion with doses of 50-250 mcg/kg/minute (mean: 173) have been used in addition to nitroprusside in a small number of patients (7 patients, 7-19 years of age, median age: 13 years) after coarctation of aorta repair (Vincent, 1990).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     An open-label trial of 20 infants and children (1 month to 12 years of age; median age: 25.6 months) used the following dosing guidelines to treat postoperative hypertension following cardiac surgery: Age &gt;1 month to 1 year: Initial: 100 mcg/kg/minute; titrate dose by 50 mcg/kg/minute every 10 minutes; age &gt;1 year to 12 years: Initial: 150 mcg/kg/minute; titrate dose by 50-100 mcg/kg/minute every 10 minutes; dose was titrated until blood pressure was &le;90th percentile for age or until maximum dose of 1000 mcg/kg/minute was reached; mean required dose: 700 mcg/kg/minute (range: 300-1000 mcg/kg/minute); final dose required was significantly higher in patients with aortic coarctation repair (mean &plusmn; SD: 830 &plusmn; 153 mcg/kg/minute) than in patients with repair of other congenital heart defects (mean &plusmn; SD: 570 &plusmn; 230 mcg/kg/minute) (Wiest, 1998)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intraoperative tachycardia and/or hypertension (immediate control): Loading dose: 80 mg (~1 mg/kg) over 30 seconds; follow with a 150 mcg/kg/minute infusion, if necessary; adjust infusion rate as needed to maintain desired heart rate and/or blood pressure; maximum dose: 300 mcg/kg/minute.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Supraventricular tachycardia or gradual control of postoperative tachycardia and hypertension: Loading dose: 500 mcg/kg over 1 minute; follow with a 50 mcg/kg/minute infusion for 4 minutes; if response is inadequate, rebolus with another 500 mcg/kg loading dose over 1 minute, and increase the maintenance infusion to 100 mcg/kg/minute. Repeat this process until a therapeutic effect has been achieved or to a maximum recommended maintenance dose of 200 mcg/kg/minute. Usual dosage range: 50-200 mcg/kg/minute with average dose = 100 mcg/kg/minute.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS, as hydrochloride [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brevibloc: 2000 mg (100 mL) [20 mg/mL; double strength]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brevibloc: 2500 mg (250 mL) [10 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 10 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brevibloc: 10 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Brevibloc: 20 mg/mL (5 mL [DSC]) [double strength]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes infusion",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052563\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: I.V.: Commercially available concentrations (10 mg/mL and 20 mg/mL) are iso-osmotic and can be used for direct I.V. use; infuse I.V. loading dose over 1-2 minutes.",
"     <b>",
"      Note:",
"     </b>",
"     Parenteral drug products are for single patient use only; products do",
"     <b>",
"      not",
"     </b>",
"     contain preservatives. Do not introduce additives into the premixed bags. Medication port of premixed bag should be used to withdraw only the initial bolus; do not use medication port to withdraw additional bolus doses (sterility cannot be assured).",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     10,000",
"     <b>",
"      mcg",
"     </b>",
"     /mL or 20,000",
"     <b>",
"      mcg",
"     </b>",
"     /mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F166924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     R, D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 40 mEq/L, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Alcohol (ethyl), amikacin, aminophylline, amiodarone, ampicillin, atracurium, bivalirudin, butorphanol, calcium chloride, cefazolin, ceftazidime, chloramphenicol, cimetidine, cisatracurium, clindamycin, dexmedetomidine, diltiazem, dopamine, doripenem, enalaprilat, erythromycin lactobionate, famotidine, fenoldopam, fentanyl, gentamicin, heparin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, insulin (regular), labetalol, linezolid, magnesium sulfate, methyldopate, metronidazole, micafungin, midazolam, morphine, nafcillin, nicardipine, nitroglycerin, nitroprusside, norepinephrine, pancuronium, penicillin G potassium, piperacillin, polymyxin B sulfate, potassium chloride, potassium phosphates, propofol, ranitidine, remifentanil, sodium acetate, streptomycin, sulfamethoxazole/trimethoprim, tacrolimus, terbutaline, tobramycin, vancomycin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, furosemide, lansoprazole, pantoprazole, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Sodium bicarbonate",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2975039\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); protect from freezing and excessive heat. Stable for at least 24 hours (under refrigeration or at controlled room temperature) at a final concentration of 10 mg/mL in the following solutions: D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, LR, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W with KCl 40 mEq/L;",
"     <b>",
"      not",
"     </b>",
"     compatible with sodium bicarbonate 5%",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of supraventricular tachycardia (primarily to control ventricular rate in patients with atrial fibrillation or flutter) (FDA approved in adults); noncompensatory sinus tachycardia (FDA approved in adults); perioperative tachycardia and hypertension (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F166926\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Esmolol may be confused with Osmitrol&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Brevibloc&reg; may be confused with Brevital&reg;, Bumex&reg;, Buprenex&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F166923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Asymptomatic hypotension, blood pressure decreased, peripheral ischemia, symptomatic hypotension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, confusion, dizziness, headache, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Infusion site reaction (including irritation, inflammation, and severe reactions associated with extravasation [eg, thrombophlebitis, necrosis, and blistering])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal discomfort, abnormal thinking, angioedema, anorexia, anxiety, bradycardia, bronchospasm, cardiac arrest, constipation, coronary arteriospasm, decompensated heart failure, depression, dyspepsia, flushing, heart block, hyperkalemia, lightheadedness, pallor, paresthesia, psoriasis, renal tubular acidosis, seizure, severe bradycardia/asystole (rare), syncope, urinary retention, urticaria, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to esmolol, any component, or other beta-blockers; sinus bradycardia or heart block, uncompensated CHF, cardiogenic shock",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with extreme caution in patients with hyper-reactive airway disease; in general, patients with bronchospastic disease should not receive beta-blockers; however, esmolol, with B",
"     <sub>",
"      1",
"     </sub>",
"     selectivity, has been used cautiously with close monitoring; use lowest dose possible and discontinue infusion if bronchospasm occurs; incidence less than compared to propranolol but more likely with higher doses. Use with caution in diabetes mellitus or hypoglycemia; may potentiate hypoglycemia and/or mask signs and symptoms. Use with caution in patients with renal impairment; active metabolite retained. Avoid extravasation, can lead to skin necrosis and sloughing. Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052551\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Caution should be exercised when discontinuing esmolol infusions to avoid withdrawal effects. Hypotension can commonly occur; especially with doses &gt;200 mcg/kg/minute; monitor patients closely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Beta1 Selective) may diminish the bronchodilatory effect of Theophylline Derivatives.  Management: Monitor for reduced theophylline efficacy during concomitant use with any beta-blocker.  Beta-1 selective agents are less likely to antagonize theophylline than nonselective agents, but selectivity may be lost at higher doses.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid xanthine-containing foods or beverages",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F1894141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in some animal reproduction studies. Esmolol has been shown to decrease fetal heart rate. Adverse fetal/neonatal events have also been observed with the chronic use of beta-blockers during pregnancy. Esmolol is a short-acting beta-blocker and not indicated for the chronic treatment of hypertension. Esmolol may be considered for the acute management of atrial fibrillation in pregnant women (Fuster, 2006). Esmolol has been evaluated for use during intubation as an agent to offset the exaggerated pressor response observed in pregnant women with hypertension undergoing surgery (Bansal, 2002).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, ECG, heart rate, respiratory rate, I.V. site",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Class II antiarrhythmic: Competitively blocks response to beta",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic stimulation with little or no effect on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors except at high doses (ie, cardioselective at lower doses); no intrinsic sympathomimetic activity; no membrane-stabilizing activity; ultrashort-acting",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Beta blockade occurs within 2-10 minutes (onset of effects is quickest when loading doses are administered)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Short (10-30 minutes)",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     :",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 2 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 3.5 L/kg (range: 2-5 L/kg)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In blood by esterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     18 months to 14 years (n=12): 2.88 &plusmn; 2.67 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2.5-16 years (n=20): 4.5 &plusmn; 2.1 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 9 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &sim;69% of dose excreted in urine as metabolites and 2% as unchanged drug",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bansal S and Pawar M, \"Haemodynamic Responses to Laryngoscopy and Intubation in Patients With Pregnancy-Induced Hypertension: Effect of Intravenous Esmolol With or Without Lidocaine,\"",
"      <i>",
"       Int J Obstet Anesth",
"      </i>",
"      , 2002, 11(1):4-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/15321570/pubmed\" id=\"15321570\" target=\"_blank\">",
"        15321570",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cuneo BF, Zales VR, Blahunka PC, et al, &ldquo;Pharmacodynamics and Pharmacokinetics of Esmolol, A Short-Acting Beta-Blocking Agent in Children,&rdquo;",
"      <i>",
"       Pediatr Cardiol",
"      </i>",
"      , 1994, 15(6):296-301.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/7838803 /pubmed\" id=\"7838803 \" target=\"_blank\">",
"        7838803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryd&eacute;n LE, Cannom DS, et al, \"ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation),\"",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/16904574/pubmed\" id=\"16904574\" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trippel DL, Wiest DB, and Gillette PC, &ldquo;Cardiovascular and Antiarrhythmic Effects of Esmolol in Children,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1991, 119(1):142-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/1676729/pubmed\" id=\"1676729\" target=\"_blank\">",
"        1676729",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vincent RN, Click LA, Williams HM, et al, &ldquo;Esmolol As an Adjunct in the Treatment of Systemic Hypertension After Operative Repair of Coarctation of the Aorta,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1990, 65(13):941-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/1969710 /pubmed\" id=\"1969710 \" target=\"_blank\">",
"        1969710",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiest DB, Garner SS, Uber WE, et al, &ldquo;Esmolol for the Management of Pediatric Hypertension After Cardiac Operations,&rdquo;",
"      <i>",
"       J Thorac Cardiovasc Surg",
"      </i>",
"      , 1998, 115(4):890-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/9576226/pubmed\" id=\"9576226\" target=\"_blank\">",
"        9576226",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wiest DB, Trippel DL, Gillette PC, et al, &ldquo;Pharmacokinetics of Esmolol in Children,&rdquo;",
"      <i>",
"       Clin Pharmacol Ther",
"      </i>",
"      , 1991, 49(6):618-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/48/5895/abstract-text/1676357/pubmed\" id=\"1676357\" target=\"_blank\">",
"        1676357",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13279 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5895=[""].join("\n");
var outline_f5_48_5895=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166884\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166885\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052559\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442485\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052553\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166862\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166846\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052563\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471861\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166924\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2975039\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052562\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166926\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166923\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052567\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052552\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052551\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299284\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166855\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052569\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166858\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1894141\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052558\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052550\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052565\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052566\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13279\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13279|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=related_link\">",
"      Esmolol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/27/3508?source=related_link\">",
"      Esmolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_48_5896="Identification and assessment of atrial septal defects in adults";
var content_f5_48_5896=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Identification and assessment of atrial septal defects in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5896/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5896/contributors\">",
"     Martin G St. John Sutton, MBBS, FRCP, FACC, FASE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5896/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5896/contributors\">",
"     Thomas P Graham, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5896/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5896/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5896/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/48/5896/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial septal defects (ASDs) are the most common congenital lesion in adults after bicuspid aortic valves. Although ASDs are often asymptomatic until adulthood, potential complications of an undetected lesion include irreversible pulmonary hypertension, right ventricular failure, atrial arrhythmias, paradoxical embolization and cerebral abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the methods used for assessment of ASDs and estimation of the shunt flow volume and ratio. The pathophysiology, clinical features, and management of ASDs in adults and issues related to ASD in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=see_link\">",
"     \"Pathophysiology and clinical features of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=see_link\">",
"     \"Classification and clinical features of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IDENTIFICATION OF THE DEFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with unexplained right ventricular volume overload should be referred for evaluation of possible obscure ASD, partial anomalous venous connection, or coronary sinus ASD [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/1\">",
"     1",
"    </a>",
"    ]. As recommended in the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    adult congenital heart disease (ACHD) guidelines, diagnosis of ASD by imaging techniques should include demonstration of shunting across the defect, assessment of RV volume overload, and evaluation of associated anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most patients, echocardiography provides the desired information related to the presence of an ASD, the size of the defect, and associated abnormalities or complications. It is also possible to obtain hemodynamic information, to estimate the magnitude and direction of shunt flow through the defect and to determine pulmonary artery pressures noninvasively in most patients. Because of certain limitations of echocardiography and operator-dependence, previous \"negative\" studies should not be regarded as definitive.",
"   </p>",
"   <p>",
"    Other modalities may be helpful in selected patients. These include cardiovascular magnetic resonance imaging (CMR) and cardiac catheterization; the latter is rarely performed nowadays for diagnostic purposes because all the requisite hemodynamic information can generally be obtained noninvasively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography is the imaging modality of choice for the diagnosis of ASD. Transthoracic echocardiography (TTE) is usually definitive in ostium secundum and primum defects, while transesophageal echocardiography (TEE) may aid in the sizing of defects, the diagnosis of sinus venosus defects of SVC or IVC type, and the assessment of associated congenital anomalies or other abnormalities such as anomalous pulmonary venous connection. Shunt volume, shunt ratios, and pulmonary artery pressures can be indirectly measured with Doppler echocardiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Two-dimensional TTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secundum and primum ASDs can be visualized with two-dimensional TTE. Clues to the presence of an ASD include abrupt discontinuity of the septum and slight thickening at its termination. Hypermobility of the septum, particularly in association with an abrupt discontinuity, is also suggestive. Two-dimensional TTE also may demonstrate enlargement of the right atrium, right ventricle, and pulmonary arteries, and show paradoxical motion of the interventricular septum.",
"   </p>",
"   <p>",
"    The standard view in which the area of the interatrial septum is best seen is the apical four chamber view where the interatrial septum is parallel to the ultrasound beam (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef67977 \" href=\"UTD.htm?41/45/42719\">",
"     image 1",
"    </a>",
"    ). However, an inaccurate diagnosis may result because the parallel angle of the echo beam to the atrial septum and the thinness of the fossa ovalis can cause artifactual echo dropout of the septum.",
"   </p>",
"   <p>",
"    The interatrial septum is perpendicular to the ultrasound beam in the subcostal view, which can afford complete visualization of the atrial septum. However, this image may be suboptimal, particularly in obese subjects. Off-axis apical, parasternal short axis and other non-standard views are frequently necessary to interrogate the whole interatrial septum.",
"   </p>",
"   <p>",
"    The diagnostic sensitivity of the subcostal approach was evaluated in a review of 154 patients (mean age 31 years) with a documented ASD (105 secundum, 32 primum, and 16 sinus venosus) in whom a satisfactory image of the atrial septum could be obtained by TTE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/2\">",
"     2",
"    </a>",
"    ]. The defect was successfully visualized in 89 percent of secundum ASDs, 100 percent of primum ASDs, and only 44 percent of sinus venosus ASDs. Contrast echocardiography, when performed, identified all defects missed by two-dimensional TTE.",
"   </p>",
"   <p>",
"    Since visualization of the atrial septum may be suboptimal in a TTE study, other clues to the presence of an intracardiac shunt should be assessed. Unexplained dilatation of the right atrium, right ventricle, and pulmonary arteries is suggestive of the presence of a shunt, as is paradoxical septal motion and diastolic flattening of the interventricular septum.",
"   </p>",
"   <p>",
"    The size of an ASD on two-dimensional TTE does not correlate well with shunt flow measured at catheterization. This is better assessed with color flow and pulsed-wave Doppler or three-dimensional TTE or TEE imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Agitated saline contrast",
"    </span>",
"    &nbsp;&mdash;&nbsp;If two dimensional TTE imaging and color Doppler imaging are not conclusive for ASD, agitated saline contrast injection in a peripheral vein at rest and with one or more maneuvers (Valsalva or cough) is helpful to confirm the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/1\">",
"     1",
"    </a>",
"    ]. Agitated saline contrast TTE or TEE involves the injection of microbubbles into a peripheral vein to confirm the presence of a right-to-left shunt. An adequate contrast injection causes opacification of the right atrium and ventricle. If there is a right-to-left interatrial shunt, early appearance of contrast can be seen in the left atrium. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=see_link\">",
"     \"Contrast echocardiography: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A right-to-left interatrial shunt can be detected by contrast echocardiography, usually with transesophageal echocardiography, in three circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With reversal of flow through an uncomplicated ASD when right-sided pressure is transiently increased (eg, with a Valsalva maneuver or coughing) or briefly during the onset of left ventricular contraction (",
"      <a class=\"graphic graphic_movie graphicRef61938 \" href=\"UTD.htm?18/42/19106\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef67067 \" href=\"UTD.htm?8/49/8983\">",
"       movie 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      With an ASD complicated by pulmonary hypertension, in which the left-to-right shunt is reversed.",
"     </li>",
"     <li>",
"      With a patent foramen ovale, in which the flow is, by definition, from right-to-left (",
"      <a class=\"graphic graphic_movie graphicRef56656 \" href=\"UTD.htm?32/20/33094\">",
"       movie 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link\">",
"       \"Patent foramen ovale\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contrast echocardiography also may be used in the detection of a left-to-right shunt. Negative contrast in the right atrium is a helpful but insensitive sign for the diagnosis of left-to-right interatrial shunting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. In this setting, flow from the contrast-free left atrium produces areas in the right atrium in which contrast is not seen (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70404 \" href=\"UTD.htm?23/59/24498\">",
"     image 2",
"    </a>",
"    ). Care must be taken to distinguish this finding from lack of contrast opacification of the right atrium due to streaming of blood from vena cava inflow.",
"   </p>",
"   <p>",
"    Although there are only scant reports of complications from agitated saline contrast, we do not perform contrast injections in pregnant patients or those with severe pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=see_link&amp;anchor=H8#H8\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\", section on 'Agitated saline safety'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Color flow, pulsed, and continuous wave Doppler all provide information in patients with an ASD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link\">",
"     \"Principles of Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The addition of color flow Doppler imaging can confirm the presence of an ASD, estimate the defect size, the overall direction of the flow across the atrial septum, the suitability of percutaneous device closure, and assessment of the efficacy of surgery. A shunt across an ASD typically shows turbulent flow in the direction of the shunt and minimal flow in the opposite direction (",
"    <a class=\"graphic graphic_movie graphicRef80448 \" href=\"UTD.htm?6/56/7040\">",
"     movie 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_movie graphicRef54350 \" href=\"UTD.htm?40/32/41487\">",
"     movie 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The maximal width of the color flow jet across the interatrial septum in the view from which it is best visualized correlates well with the size of the shunt at catheterization. A jet width greater than 15 mm can distinguish patients with a shunt ratio of greater than 2:1 (an indication for closure of the ASD) from those with a lesser shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are several limitations to color flow Doppler in the diagnosis of ASD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It may not visualize shunt flow if the frame rate is too slow, since flow across the ASD may occur only during a portion of the cardiac cycle. Reducing the Nyquist limit (the upper limit of velocity that can be detected with a given Doppler pulse frequency) may allow the turbulent flow to be detected.",
"     </li>",
"     <li>",
"      Ghosting of color across the interatrial septum sometimes gives the false impression of shunt flow.",
"     </li>",
"     <li>",
"      Sinus venosus defects, that are high or low in the septum (",
"      <a class=\"graphic graphic_figure graphicRef52106 \" href=\"UTD.htm?7/36/7748\">",
"       figure 1",
"      </a>",
"      ), may not be visualized with TTE (only seen in 7 of 16 patients were identified in one report) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/2\">",
"       2",
"      </a>",
"      ]. A sinus venosus defect is one of the disorders that should be suspected in a patient with right heart enlargement and features of shunt physiology who has no evidence for an ASD or a VSD on TTE. Agitated saline contrast or TEE can identify almost all of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/2\">",
"       2",
"      </a>",
"      ], while CMR imaging or cardiac catheterization is less often performed.",
"     </li>",
"     <li>",
"      Estimation of jet width size does not take into account shunt flow due to associated anomalous pulmonary venous connections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pulsed Doppler permits sampling of blood flow velocities from a specific region of interest. It is particularly useful for assessing relatively low velocity flows and can therefore identify flow across the atrial septum and indirectly indicate the pulmonary flow to systemic flow ratio. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Estimation of shunt flow ratio and volume'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=see_link\">",
"     \"Principles of Doppler echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In comparison, continuous-wave Doppler echocardiography is particularly useful for assessing high velocity flows. As a result, it can be used to evaluate the gradient across the atrial septum in patients with left atrial hypertension and restrictive ASDs and to assess obstruction to pulmonary venous return [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     TEE",
"    </span>",
"    &nbsp;&mdash;&nbsp;TEE is superior to TTE for imaging the interatrial septum and pulmonary veins and is often used when a definitive diagnosis is not made by TTE and in patients with chest wall deformities and lung disease in whom TTE windows may be technically limited.",
"   </p>",
"   <p>",
"    TEE has the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is extremely accurate for the diagnosis of all types of septal defects (",
"      <a class=\"graphic graphic_movie graphicRef79348 \" href=\"UTD.htm?22/39/23167\">",
"       movie 6",
"      </a>",
"      ). It may be particularly important for sinus venosus defects, which are often missed with TTE [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When performed with contrast or color flow Doppler, it can detect right-to-left shunting when there is transient reversal of flow through the ASD when right-sided pressure is increased (eg, with a Valsalva maneuver) or briefly during the onset of left ventricular contraction (",
"      <a class=\"graphic graphic_movie graphicRef61938 \" href=\"UTD.htm?18/42/19106\">",
"       movie 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef79804 \" href=\"UTD.htm?17/43/18098\">",
"       movie 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      It is more sensitive than TTE for the detection of left-to-right shunting as negative right atrial contrast (93 versus 58 percent in one report) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It can detect flow through multiple ASDs (",
"      <a class=\"graphic graphic_movie graphicRef59313 \" href=\"UTD.htm?3/43/3775\">",
"       movie 8",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Estimation of defect size using the diameter of the Doppler color flow jet correlates with surgical findings.",
"     </li>",
"     <li>",
"      TEE imaging also can be used to identify pulmonary venous connections; however, anomalous venous connection to the superior or inferior vena cava may be out of the imaging plane [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/7\">",
"       7",
"      </a>",
"      ]. In this setting, CMR can be used to define the anatomy of the anomalous venous connections.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31860519\">",
"    <span class=\"h3\">",
"     Three-dimensional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three-dimensional echocardiography is an investigational technique [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. It can facilitate precise sizing of ASDs and provide information that may be important for treatment (eg, trans-catheter closure), such as the relationship of the ASD to atrial superior and inferior limbic band tissue and to the AV valves. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=see_link\">",
"     \"Three-dimensional echocardiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transcranial Doppler",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transcranial contrast Doppler ultrasound is an alternative method for detecting right-to-left shunts due to a PFO [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. With this technique, a probe is placed against the side of the skull just above the zygomatic arch (ie, over the middle cerebral artery). A contrast agent is injected and Doppler ultrasonography is performed at baseline and after a Valsalva maneuver [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=see_link\">",
"     \"Contrast echocardiography: Contrast agents, safety, and imaging technique\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Transcranial contrast Doppler appears to have comparable sensitivity and specificity to contrast TEE [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], and has the advantages of being noninvasive and of providing a quantitative assessment of the number of microbubbles reaching the brain. However, it gives no anatomic information regarding the cardiac site and nature of the shunt and may be prone to false positive results in patients with intrapulmonary shunts [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2004 assessment report from the American Academy of Neurology concluded that TEE was superior to transcranial Doppler because it provides direct anatomic information regarding the site and nature of the shunt and the possible presence of an atrial septal aneurysm [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=see_link&amp;anchor=H15#H15\">",
"     \"Patent foramen ovale\", section on 'Diagnosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=see_link&amp;anchor=H6#H6\">",
"     \"Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults\", section on 'Atrial septal aneurysm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cardiovascular magnetic resonance imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMR imaging can be used to determine defect location and size, estimate shunt flow, and detect anomalous venous connections [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. In a study of 30 patients with ASD, defect size estimated from CMR was compared to defect size determined at catheterization and surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/18\">",
"     18",
"    </a>",
"    ]. Phase contrast cine MR accurately estimated the size of all three types of ASD, while spin echo MR substantially overestimated the diameter and area of the ASD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Radionuclide angiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;First pass radionuclide angiography (RNA) has been used successfully to detect intracardiac shunting. Rapid bolus injection of a radionuclide with gamma camera imaging is used to detect early recirculation of blood from the left heart to the lungs. Radionuclide studies have also been used in the past for shunt quantification, but this technique has been superseded by other methods. In a comparative study of RNA and cine CMR in 16 patients, only eight patients had an adequate RNA study due to either poor bolus quality (five patients) or concurrent right-to-left shunting (three patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/22\">",
"     22",
"    </a>",
"    ]. In contrast, CMR was able to provide accurate shunt measurements in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Determination of the presence of an ASD by catheterization involves sampling of the oxygen content in the inferior vena cava, superior vena cava, right atrium, right ventricle, and pulmonary artery; a \"step-up\" in oxygen saturation is indicative of a left-to-right shunt. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\", section on 'Detection of left to right shunts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac catheterization, because it is invasive, is rarely indicated for diagnostic purposes in patients with an ASD. However, when pulmonary vascular disease is suspected, measurement of the pulmonary vascular resistance is important in determining whether closure of the defect is indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link&amp;anchor=H5#H5\">",
"     \"Management and outcome of isolated atrial septal defects in children\", section on 'Which ASDs should be closed?'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of atrial septal defects in adults\", section on 'Fixed pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cineangiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cineangiography can be used to confirm the presence of an ASD with left-to-right shunting. Optimal direct visualization is achieved by an injection of contrast just outside the orifice of the right upper pulmonary vein in the cranially angulated left anterior oblique projection (also known as the four-chamber view). With this view, secundum ASDs are seen in the middle of the atrial septum, and sinus venous and AV canal defects are seen at the superior and inferior aspect of the atrial septum, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ESTIMATION OF SHUNT FLOW RATIO AND VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative closure of an ASD has traditionally been recommended when the ratio of pulmonary blood flow to systemic blood flow",
"    <span class=\"nowrap\">",
"     (Qp/Qs)",
"    </span>",
"    is greater than 1.5:1 to 2:1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=see_link\">",
"     \"Management and outcome of isolated atrial septal defects in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=see_link\">",
"     \"Management of atrial septal defects in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Doppler echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    ratio can be estimated with pulsed Doppler echocardiography using the TTE approach. Compared to the gold standard of cardiac catheterization, pulsed Doppler echocardiography is noninvasive and easily permits serial monitoring. Thus, once an acceptable correlation between echocardiographic and catheterization laboratory estimates of shunt flow has been established for an individual laboratory, it is not unreasonable to forgo cardiac catheterization in young patients when possible associated anomalies have been ruled out by TEE.",
"   </p>",
"   <p>",
"    With pulsed Doppler echocardiography, the stroke volume through each valve is measured using the following formula:",
"   </p>",
"   <p>",
"    &nbsp;Stroke volume &nbsp;= &nbsp;cross sectional area &nbsp;x &nbsp;velocity time integral (VTI) of the Doppler flow signal",
"   </p>",
"   <p>",
"    Left-sided stroke volume is measured from the left ventricular outflow tract (LVOT) by assuming a circular geometry. The diameter of the LVOT is always measured in the parasternal long axis view. The maximum Doppler flow velocity apical to the aortic valve (VTI-LVOT) is taken in the apical four chamber view. The right-sided velocity time integral (VTI-PA) is measured in the pulmonary artery well before the bifurcation. The diameter of the pulmonary artery (PA) is then measured at the same location. Substitution into the stroke volume formula results in the following formula:",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    = &nbsp;[PA diameter(2) &nbsp;x &nbsp;VTI-PA] &nbsp;&divide; &nbsp;[LVOT diameter(2) &nbsp;x &nbsp;VTI-LVOT]",
"   </p>",
"   <p>",
"    The number two in parentheses (2) refers to the square of the LVOT or PA diameter.",
"   </p>",
"   <p>",
"    The equation requires that the diameters of the LVOT and PA be squared, making exact measurements of these diameters of prime importance in the calculation of the shunt ratio. Measurement of the PA diameter, taken in the parasternal short axis view at the base of the heart, can be problematic in some patients, in which case the PA can be measured in the subcostal view in which the main PA is visualized in its long axis. Thus, this is the term in the equation that is most often responsible for inaccurate estimates of the shunt ratio. Nevertheless, this method correlates well with catheterization in patients with adequate TTE views [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Shunt flow volume can be estimated using the area of the defect (again assuming a circular geometry) and the velocity time integral of the shunt flow measured with the Doppler beam parallel to shunt direction [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/24\">",
"     24",
"    </a>",
"    ]. Methods have also been developed to assess shunt volume using three-dimensional color Doppler echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Serial monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because ASDs often enlarge over time in children and adults, serial TTE monitoring of clinical status, right heart size and function, and",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    (if feasible by TTE) is warranted in asymptomatic patients who are managed medically. Adults with small ASDs without evidence of right ventricular enlargement or pulmonary artery hypertension should be followed for development of symptoms and receive a repeat TTE every two to three years to evaluate right ventricular size and function and pulmonary arterial pressures [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456464\">",
"    <span class=\"h2\">",
"     CMR",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, CMR can measure the",
"    <span class=\"nowrap\">",
"     Qp/Qs",
"    </span>",
"    noninvasively and is helpful if echocardiographic findings are equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5896/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=see_link&amp;anchor=H34#H34\">",
"     \"Clinical utility of cardiovascular magnetic resonance imaging\", section on 'Congenital heart disease'",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Cardiac catheterization",
"    </span>",
"    &nbsp;&mdash;&nbsp;A formal \"shunt run\" at cardiac catheterization measures the oxygen content in the blood at multiple sites, and the Fick equation is then used to calculate the ratio of pulmonary to systemic flow",
"    <span class=\"nowrap\">",
"     (Qp/Qs)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef78106 \" href=\"UTD.htm?41/32/42510\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary artery catheterization: Interpretation of tracings\", section on 'Detection of left to right shunts'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The sequence of steps in this determination is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The \"shunt run\" is performed, measuring oxygen saturation in the inferior vena cava (IVC), superior vena cava (SVC), right atrium (RA), right ventricle (RV), and pulmonary artery (PA). Accurate catheter position during this procedure is essential. Mixed venous oxygen saturation (MvO2) can then be calculated as follows:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp;MvO2 = [(3 &nbsp;x &nbsp;SVC oxygen saturation) &nbsp;+ &nbsp;(IVC oxygen saturation)]",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    4",
"   </p>",
"   <p>",
"    The SVC oxygen saturation is multiplied by three because SVC flow is approximately three times IVC flow.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic arterial oxygen saturation (SaO2) is measured by arterial blood gas analysis or by pulse oximetry. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=see_link\">",
"       \"Pulse oximetry\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Oxygen (O2) consumption is determined (this assessment should be based upon direct measurement, rather than assumed from available nomograms). This measurement requires substantial patient cooperation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=see_link\">",
"       \"Oxygen delivery and consumption\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The patient's blood hemoglobin concentration ([Hgb]) is obtained from a complete blood count or blood gas analysis.",
"     </li>",
"     <li>",
"      The systemic blood flow (Qs) is calculated from the Fick equation (",
"      <a class=\"graphic graphic_figure graphicRef78106 \" href=\"UTD.htm?41/32/42510\">",
"       figure 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Qs &nbsp;= &nbsp;(O2 consumption) &nbsp;&divide; &nbsp;(13.4 &nbsp;x &nbsp;[Hgb] &nbsp;x &nbsp;[SaO2 - MvO2])",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pulmonary blood flow (Qp) is also calculated from the Fick equation (",
"      <a class=\"graphic graphic_figure graphicRef78106 \" href=\"UTD.htm?41/32/42510\">",
"       figure 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Qp &nbsp;= &nbsp;(O2 consumption) &nbsp;&divide; &nbsp;(13.4 &nbsp;x &nbsp;[Hgb] &nbsp;x &nbsp;[pulmonary venous O2 saturation &nbsp;- &nbsp;PA O2 saturation])",
"   </p>",
"   <p>",
"    This calculation requires a value for the pulmonary venous O2 saturation, which is not usually measured directly (although a catheter can be inserted across the ASD and into the pulmonary veins). If the SaO2 is above 95 percent, it may be used as an approximation of the pulmonary venous measurement.",
"   </p>",
"   <p>",
"    If the SaO2 is less than 95 percent, a right-to-left shunt may be present and must be excluded by contrast echocardiography or other means. An SaO2 of less than 95 percent not due to a right-to-left shunt (eg, due to chronic lung disease) should be used as the accurate estimate of the pulmonary venous O2 saturation. If a right-to-left shunt is present, an assumed value of 98 percent for the pulmonary venous O2 saturation is used.",
"   </p>",
"   <p>",
"    With the results of the Qp and Qs determinations, the shunt flow ratio and volume can be determined. The shunt ratio is",
"    <span class=\"nowrap\">",
"     Qp/Qs.",
"    </span>",
"    If there is no evidence of an associated right-to-left shunt, the volume of the left-to-right shunt is determined as Qp - Qs. More complex calculations are required to determine shunt volume in the presence of bidirectional shunting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H456237\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of atrial septal defect (ASD) by imaging techniques should include demonstration of shunting across the defect, assessment of RV volume overload, and evaluation of any associated anomalies. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Identification of the defect'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Echocardiography is the imaging modality of choice for the diagnosis of ASD. Transthoracic echocardiography (TTE) is usually definitive in ostium secundum and primum defects, while transesophageal echocardiography (TEE) may aid in the sizing of defects, the diagnosis of sinus venosus defects of SVC or IVC type, and the assessment of associated anomalies such as anomalous pulmonary venous connection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with unexplained dilatation of the right atrium or right ventricle should be evaluated by Doppler echocardiography for possible ASD. An agitated saline contrast study at rest and with maneuvers is suggested if comprehensive TTE imaging is inconclusive. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Echocardiography'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adults with small ASDs without evidence of right ventricular enlargement or pulmonary artery hypertension should be followed for development of symptoms and receive a repeat Doppler echocardiogram every two to three years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29808924\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. Susan Wiegers for her contributions as an author to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/1\">",
"      Warnes CA, Williams RG, Bashore TM, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 2008; 118:e714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/2\">",
"      Shub C, Dimopoulos IN, Seward JB, et al. Sensitivity of two-dimensional echocardiography in the direct visualization of atrial septal defect utilizing the subcostal approach: experience with 154 patients. J Am Coll Cardiol 1983; 2:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/3\">",
"      Konstantinides S, Kasper W, Geibel A, et al. Detection of left-to-right shunt in atrial septal defect by negative contrast echocardiography: a comparison of transthoracic and transesophageal approach. Am Heart J 1993; 126:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/4\">",
"      Suzuki Y, Kambara H, Kadota K, et al. Detection of intracardiac shunt flow in atrial septal defect using a real-time two-dimensional color-coded Doppler flow imaging system and comparison with contrast two-dimensional echocardiography. Am J Cardiol 1985; 56:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/5\">",
"      Pollick C, Sullivan H, Cujec B, Wilansky S. Doppler color-flow imaging assessment of shunt size in atrial septal defect. Circulation 1988; 78:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/6\">",
"      Vick GW 3rd, Murphy DJ Jr, Ludomirsky A, et al. Pulmonary venous and systemic ventricular inflow obstruction in patients with congenital heart disease: detection by combined two-dimensional and Doppler echocardiography. J Am Coll Cardiol 1987; 9:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/7\">",
"      Roberson DA, Muhiudeen IA, Silverman NH, et al. Intraoperative transesophageal echocardiography of atrioventricular septal defect. J Am Coll Cardiol 1991; 18:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/8\">",
"      Marx GR, Fulton DR, Pandian NG, et al. Delineation of site, relative size and dynamic geometry of atrial septal defects by real-time three-dimensional echocardiography. J Am Coll Cardiol 1995; 25:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/9\">",
"      Acar P, Roux D, Dulac Y, et al. Transthoracic three-dimensional echocardiography prior to closure of atrial septal defects in children. Cardiol Young 2003; 13:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/10\">",
"      Marx GR, Sherwood MC, Fleishman C, Van Praagh R. Three-dimensional echocardiography of the atrial septum. Echocardiography 2001; 18:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/11\">",
"      Droste DW, Lakemeier S, Wichter T, et al. Optimizing the technique of contrast transcranial Doppler ultrasound in the detection of right-to-left shunts. Stroke 2002; 33:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/12\">",
"      Schwarze JJ, Sander D, Kukla C, et al. Methodological parameters influence the detection of right-to-left shunts by contrast transcranial Doppler ultrasonography. Stroke 1999; 30:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/13\">",
"      Albert A, M&uuml;ller HR, Hetzel A. Optimized transcranial Doppler technique for the diagnosis of cardiac right-to-left shunts. J Neuroimaging 1997; 7:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/14\">",
"      Job FP, Ringelstein EB, Grafen Y, et al. Comparison of transcranial contrast Doppler sonography and transesophageal contrast echocardiography for the detection of patent foramen ovale in young stroke patients. Am J Cardiol 1994; 74:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/15\">",
"      Nemec JJ, Marwick TH, Lorig RJ, et al. Comparison of transcranial Doppler ultrasound and transesophageal contrast echocardiography in the detection of interatrial right-to-left shunts. Am J Cardiol 1991; 68:1498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/16\">",
"      Droste DW, Schmidt-Rimpler C, Wichter T, et al. Right-to-left-shunts detected by transesophageal echocardiography and transcranial Doppler sonography. Cerebrovasc Dis 2004; 17:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/17\">",
"      Sloan MA, Alexandrov AV, Tegeler CH, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2004; 62:1468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/18\">",
"      Holmvang G, Palacios IF, Vlahakes GJ, et al. Imaging and sizing of atrial septal defects by magnetic resonance. Circulation 1995; 92:3473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/19\">",
"      Brenner LD, Caputo GR, Mostbeck G, et al. Quantification of left to right atrial shunts with velocity-encoded cine nuclear magnetic resonance imaging. J Am Coll Cardiol 1992; 20:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/20\">",
"      Powell AJ, Tsai-Goodman B, Prakash A, et al. Comparison between phase-velocity cine magnetic resonance imaging and invasive oximetry for quantification of atrial shunts. Am J Cardiol 2003; 91:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/21\">",
"      Beerbaum P, K&ouml;rperich H, Esdorn H, et al. Atrial septal defects in pediatric patients: noninvasive sizing with cardiovascular MR imaging. Radiology 2003; 228:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/22\">",
"      Mohiaddin RH, Underwood R, Romeira L, et al. Comparison between cine magnetic resonance velocity mapping and first-pass radionuclide angiocardiography for quantitating intracardiac shunts. Am J Cardiol 1995; 75:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/23\">",
"      Dittmann H, Jacksch R, Voelker W, et al. Accuracy of Doppler echocardiography in quantification of left to right shunts in adult patients with atrial septal defect. J Am Coll Cardiol 1988; 11:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/24\">",
"      Mehta RH, Helmcke F, Nanda NC, et al. Transesophageal Doppler color flow mapping assessment of atrial septal defect. J Am Coll Cardiol 1990; 16:1010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5896/abstract/25\">",
"      Hofmann T, Franzen O, Koschyk DH, et al. Three-dimensional color Doppler echocardiography for assessing shunt volume in atrial septal defects. J Am Soc Echocardiogr 2004; 17:1173.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1416 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-210.101.131.232-54E23519EC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5896=[""].join("\n");
var outline_f5_48_5896=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H456237\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IDENTIFICATION OF THE DEFECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Two-dimensional TTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Agitated saline contrast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Doppler",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - TEE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31860519\">",
"      - Three-dimensional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transcranial Doppler",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Radionuclide angiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cineangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ESTIMATION OF SHUNT FLOW RATIO AND VOLUME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Serial monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H456464\">",
"      CMR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H456237\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29808924\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1416\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1416|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?41/45/42719\" title=\"diagnostic image 1\">",
"      Apical 4 chamber ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/59/24498\" title=\"diagnostic image 2\">",
"      Contrast echo ASD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1416|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/36/7748\" title=\"figure 1\">",
"      Atrial septal defect anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/32/42510\" title=\"figure 2\">",
"      Fick shunt calculation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1416|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?18/42/19106\" title=\"movie 1\">",
"      TEE contrast atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?8/49/8983\" title=\"movie 2\">",
"      TEE contrast atrial septal aneurysm and defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?32/20/33094\" title=\"movie 3\">",
"      TEE PFO with contrast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?6/56/7040\" title=\"movie 4\">",
"      TTE two ASDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?40/32/41487\" title=\"movie 5\">",
"      TTE with color Doppler post-ASD repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?22/39/23167\" title=\"movie 6\">",
"      TEE ASD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?17/43/18098\" title=\"movie 7\">",
"      TEE color flow Doppler atrial septal defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"UTD.htm?3/43/3775\" title=\"movie 8\">",
"      TEE multiple atrial septal defects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/48/39689?source=related_link\">",
"      Atrial septal abnormalities (PFO, ASD, and ASA) and risk of cerebral emboli in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26201?source=related_link\">",
"      Classification and clinical features of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/3/34874?source=related_link\">",
"      Clinical utility of cardiovascular magnetic resonance imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/53/13145?source=related_link\">",
"      Contrast echocardiography: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/49/23318?source=related_link\">",
"      Contrast echocardiography: Contrast agents, safety, and imaging technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/1/38936?source=related_link\">",
"      Management and outcome of isolated atrial septal defects in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/0/25610?source=related_link\">",
"      Management of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/32/3593?source=related_link\">",
"      Patent foramen ovale",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16825?source=related_link\">",
"      Pathophysiology and clinical features of atrial septal defects in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/0/15365?source=related_link\">",
"      Principles of Doppler echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/10/44199?source=related_link\">",
"      Pulmonary artery catheterization: Interpretation of tracings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/38/23146?source=related_link\">",
"      Three-dimensional echocardiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_48_5897="Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology";
var content_f5_48_5897=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human T-lymphotropic virus type I: Virology, pathogenesis, and epidemiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5897/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5897/contributors\">",
"     David T Scadden, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5897/contributors\">",
"     Andrew R Freedman, FRCP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5897/contributors\">",
"     Paul Robertson, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5897/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5897/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5897/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5897/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/48/5897/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human T-lymphotropic virus (HTLV-I), the first human retrovirus to be discovered [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/1\">",
"     1",
"    </a>",
"    ], is estimated to infect 10 to 20 million people worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/2\">",
"     2",
"    </a>",
"    ]. This virus is the causative agent of two typically fatal diseases: adult T cell leukemia-lymphoma (ATL) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] and HTLV-I-associated myelopathy (HAM) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/6\">",
"     6",
"    </a>",
"    ], which is also known as tropical spastic paraparesis (TSP) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, virology, and pathogenic features of HTLV-I will be reviewed here. The diagnosis, disease associations, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     VIROLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;HTLV-I is an enveloped, single-stranded RNA virus of the Retroviridae family, the only human pathogen of the subfamily oncovirus, which includes HTLV-2, bovine leukemia virus (BLV), simian T cell leukemia virus (STLV) and HTLV-3 and HTLV-4 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/8\">",
"     8",
"    </a>",
"    ]. It has a diploid genome, comprised of two identical strands of positive sense RNA, each 9032 bp long. The genomic organization is similar to other retroviruses, with two long terminal repeat (LTR) sequences flanking gag, pol, and env genes (",
"    <a class=\"graphic graphic_figure graphicRef61279 \" href=\"UTD.htm?32/1/32795\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, HTLV-I also possesses a unique 1.6 kb region, termed pX, which is located between env and the 3'LTR [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/9\">",
"     9",
"    </a>",
"    ]. This region encodes a number of regulatory proteins: p40tax (Tax), p27rex, p21rex, p12, p13 and p30. HTLV-1 basic leucine zipper factor (HBZ) is encoded by the minus (complementary) strand of pX region [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/10\">",
"     10",
"    </a>",
"    ]. Of these, Tax and HBZ have been most implicated in viral pathogenesis (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Pathogenesis'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Cell entry and replication",
"    </span>",
"    &nbsp;&mdash;&nbsp;HTLV-I displays CD4 T cell tropism, but virion entry to CD4 T cells occurs most efficiently by direct cell-to-cell contact, rather than from virions free in plasma. Cell-free HTLV-1 can also infect dendritic cells (via",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    sulphate proteoglycans and neuropilin-1) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/11\">",
"     11",
"    </a>",
"    ] and can subsequently be transmitted from dendritic cells to CD4 T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/12\">",
"     12",
"    </a>",
"    ]. The glucose transporter, glut-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], has also been identified as a receptor for the HTLV-1 envelope glycoprotein (env). However, cells lacking GLUT-1 expression can be infected by HTLV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After entering the cell, the RNA genome of HTLV-I is reverse transcribed, generating a DNA product that integrates randomly into the host genome. Following integration, viral replication occurs only with each mitotic cell division. This results in a low viral replication rate and, given that replication is driven by host rather than by viral DNA polymerase, a high fidelity of transcription. These factors combine to explain the high genetic stability of HTLV-I [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HTLV-I regulates its own transcription via Tax, which acts as a transcriptional activator [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], and Rex, which acts to suppress transcription by regulating viral mRNA splicing. The opposing actions of Tax and Rex result in transient expression of viral gene products, which may assist in evasion of the host immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/19\">",
"     19",
"    </a>",
"    ]. When integrated as provirus, persistent infection is established, and subsequent translation of viral products can induce numerous cellular changes favoring cell survival and proliferation. Infection does not induce any cytopathic effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proviral load determination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In asymptomatic infection, approximately 0.1 to 1 percent of peripheral blood mononuclear cells (PBMCs) carry provirus (viral DNA within the host cell genome), while higher proviral loads (up to 30 percent of PBMCs) are associated with",
"    <span class=\"nowrap\">",
"     HAM/TSP.",
"    </span>",
"    Asymptomatic carriers with high proviral loads are more likely to progress to",
"    <span class=\"nowrap\">",
"     HAM/TSP",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/20\">",
"     20",
"    </a>",
"    ]. Proviral load is independent of age or sex [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/21\">",
"     21",
"    </a>",
"    ], but varies with the natural history of the infection. A prospective study of 10 patients who acquired transfusion-related HTLV-I showed a median proviral load of 212 copies per 10(5) lymphocytes within three months of infection, decreasing to 27 copies per 10(5) lymphocytes at 14 months of infection, or longer [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/22\">",
"     22",
"    </a>",
"    ]. A further study examining HTLV-1 viral load in 30 individuals over a median of 10.4 years found a minor decrease over time (-0.017 log",
"    <span class=\"nowrap\">",
"     copies/10(6)",
"    </span>",
"    <span class=\"nowrap\">",
"     PBMCs/year)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/23\">",
"     23",
"    </a>",
"    ]. A negative association with alcohol use and a positive association with black race were noted.",
"   </p>",
"   <p>",
"    Differences in proviral load between individuals infected with identical viral sequences suggest that host factors contribute most to proviral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/24\">",
"     24",
"    </a>",
"    ]. Polymorphisms in certain host MHC class I molecules have been shown to influence the proviral set-point [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/25\">",
"     25",
"    </a>",
"    ], implicating antigen presentation to CD8 T cells as an important step in viral control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HTLV-I shares many similarities with human immunodeficiency virus type 1 (HIV-1) but differs significantly from HIV-1 in the spectrum of diseases caused and the manner by which it causes them. Two virologic differences between HIV-1 and HTLV-I help to account for this:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The low replication rate and the high fidelity of replication of HTLV-I result in a relatively low viral burden and high genetic stability, thereby reducing the possibility of immune escape.",
"     </li>",
"     <li>",
"      HTLV-I does not induce death of T cells, but rather causes cell proliferation and transformation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The two diseases predominantly associated with HTLV-I, ATL and",
"    <span class=\"nowrap\">",
"     HAM/TSP,",
"    </span>",
"    rarely overlap. Further, each is associated with a different route of transmission (ATL with breast feeding, and",
"    <span class=\"nowrap\">",
"     HAM/TSP",
"    </span>",
"    with blood transfusion), and each has different pathogenic and immunologic correlates. Overall, this suggests that HTLV-I infection can result in two fundamentally different disease processes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=see_link\">",
"     \"Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cellular transformation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although HTLV-I is oncogenic, it neither induces transformation by encoding oncogenes, nor does it integrate into the host genome to disrupt host gene expression. Rather, oncogenesis is mediated through viral gene products interacting with host proteins (often transcription factors), thereby altering their function. This is typified by Tax, a 40 kDa nuclear phosphoprotein. It is the molecule most associated with HTLV-I pathogenesis and has been shown to be both necessary and sufficient to induce cellular transformation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/26-29\">",
"     26-29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tax has no human homologue [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/30\">",
"     30",
"    </a>",
"    ], but it is able to affect several signaling pathways, including NF-kB, CREB, SRF and AP-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/31\">",
"     31",
"    </a>",
"    ], in three distinct ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tax can transactivate many genes favoring T cell proliferation (including interleukin [IL]-2, IL-2Ra and IL-15), and inhibiting apoptosis (Bcl-XL).",
"     </li>",
"     <li>",
"      Tax can trans-repress genes controlling cell cycle (p18 INK4c and lck) and DNA repair (DNA polymerase b) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tax can also bind to and functionally inactivate proteins, such as the cell cycle regulator p16INK4a, the oncosuppressor TGF-beta and the mitotic checkpoint controller MAD-1 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tax can also impair the action of the cell cycle regulator p53, although the mechanism is not fully understood. The net outcome of these effects in the infected cell is to promote cell proliferation, induce genetic instability, and inhibit apoptosis, leading to the persistent clonal expansion of infected cells and the promotion of oncogenesis.",
"   </p>",
"   <p>",
"    HBZ has also been implicated in the pathogenesis of ATL and, unlike Tax, is uniformly expressed in ATL cells [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/10,34\">",
"     10,34",
"    </a>",
"    ]. Both HBZ RNA and the protein it encodes have been shown to induce changes with the RNA altering cell proliferation and the protein suppressing Tax-mediated viral transcription. The precise mechanisms by which HBZ participates in leukemogenesis have not yet been elucidated, although its selective inhibition of the classical NF-kappaB pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/35\">",
"     35",
"    </a>",
"    ] and ability to induce T-cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/36\">",
"     36",
"    </a>",
"    ] may be relevant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Immunologic control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both cellular and humoral responses are mounted against HTLV-I. Antibodies to gag proteins are produced within the first two months of infection, followed by antibodies specific for env proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/37\">",
"     37",
"    </a>",
"    ]. Anti-tax antibodies develop later in approximately half of those infected. Tax antibodies may play a role in pathogenesis of",
"    <span class=\"nowrap\">",
"     HAM/TSP,",
"    </span>",
"    given that higher anti-Tax antibody levels are associated with higher proviral load [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/38\">",
"     38",
"    </a>",
"    ] and development of",
"    <span class=\"nowrap\">",
"     HAM/TSP",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HTLV-specific cytotoxic T lymphocytes (CTLs) can readily be found in most HTLV-associated diseases, as well as in asymptomatic carriers, and are thought to be important in viral control. These cells primarily respond to epitopes from the Tax protein [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Mutations in Tax resulting in viral escape from CTL killing have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/42\">",
"     42",
"    </a>",
"    ]. Epitopes within other proteins, such as the gp46 envelope glycoprotein [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/43\">",
"     43",
"    </a>",
"    ], have also been described. The significance of HTLV-specific T cells in",
"    <span class=\"nowrap\">",
"     HAM/TSP",
"    </span>",
"    or ATL remains poorly defined. Impaired function of CTLs in both disease states has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/44-46\">",
"     44-46",
"    </a>",
"    ], although it is unclear what factors result in this functional impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HTLV-I infects an estimated 10 to 20 million people worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/2\">",
"     2",
"    </a>",
"    ] and is primarily transmitted by breast feeding, although spread via blood transfusion, sharing of needles, and sexual intercourse also occurs. This predominance of vertical transmission results in clustering of cases in familial or geographically discrete groups. It is endemic in southern Japan, the Caribbean, South America, the Melanesian islands, Papua New Guinea, the Middle East and central and southern Africa. In these endemic areas, seroprevalences range from three to five percent in Trinidad [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/47\">",
"     47",
"    </a>",
"    ] up to 30 percent in rural Miyazaki in southern Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, non-endemic areas, such as the United States and Europe, have prevalence rates of less than 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Seroprevalence tends to increase with age, and women are nearly twice as likely to be infected as men [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/48,51\">",
"     48,51",
"    </a>",
"    ], although the gender difference is only seen after 30 years of age and probably reflects the relative efficiency of sexual transmission from male to female [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/52\">",
"     52",
"    </a>",
"    ]. In Southern Japan, the seroprevalence rate among pregnant women is approximately 5 percent. This can be contrasted with much lower seropositivity in non-endemic areas in Japan (0.1 to 1 percent), a result similar to serologic studies from Europe.",
"   </p>",
"   <p>",
"    HTLV-I displays little genomic variability during the course of infection or between patients in the same geographic area.",
"    <span class=\"nowrap\">",
"     Mother/child",
"    </span>",
"    and spouse pairs from Okinawa, Japan have been shown to be infected with highly conserved, and often identical, viruses based upon direct sequencing of the viral genome [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/16\">",
"     16",
"    </a>",
"    ]. Studies in France [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/53\">",
"     53",
"    </a>",
"    ], Papua New Guinea, the Solomon Islands [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/54\">",
"     54",
"    </a>",
"    ], and Zaire [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/55\">",
"     55",
"    </a>",
"    ] have shown similarly low genomic variability based upon the less accurate sequencing of PCR products. There is recognized strain variation between geographic areas, but this variation is small.",
"   </p>",
"   <p>",
"    The risk of transmission appears to be independent of HLA class 1 type, but is modestly increased by greater HLA class 1 matching between mother and child (threefold increased risk with five or six shared HLA class 1 types) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/56\">",
"     56",
"    </a>",
"    ]. Susceptibility of infection in African children has been linked to chromosome 6q27, [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Breast feeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;HTLV-I antigen is found in the milk of infected mothers [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/58\">",
"     58",
"    </a>",
"    ]; animal models have shown that breast milk alone can transmit HTLV-I [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/59\">",
"     59",
"    </a>",
"    ]; and risk of infection is higher in breast-fed infants than in those who are bottle fed. Over a one-year period, breast-fed infants have a fourfold increase risk of infection (15.7 versus 3.6 percent). These findings strongly support the hypothesis that virus can be spread though breast feeding, probably through lymphocytes in milk. Overall, the risk of transmission via breast feeding is estimated to be approximately 16 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/60,61\">",
"     60,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A longer duration of breast feeding increases transmission risk. In a prospective study of 780 Japanese infants, those who were breast fed for seven months or more had a rate of seroconversion to HTLV-I of 14.4 percent, while those breast fed for six months or less seroconverted at an equivalent rate as bottle-fed infants (4.4 and 5.7 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/62\">",
"     62",
"    </a>",
"    ]. Similar findings have been reported in smaller but prospective studies in Japan [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/63\">",
"     63",
"    </a>",
"    ] and Jamaica [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another important risk factor is the provirus load in breast milk. This was illustrated in a report from Jamaica in which the risk of transmission ranged from 4.7 to 28.7 per 1000 person months at low and high provirus loads, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is likely that the presence of maternal antibodies transferred in utero is protective for some months after birth. A prospective study of breast-fed infants born to seropositive mothers showed that infants seropositive at two years of age remained seropositive (for at least 10 years), but for infants who were seronegative at 2 years, no further transmission was seen [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/66\">",
"     66",
"    </a>",
"    ]. These results suggested that after the period of breastfeeding, the risks of transmission were small prior to puberty.",
"   </p>",
"   <p>",
"    Animal models have demonstrated the effectiveness of virus-specific immunoglobulin given prophylactically to prevent HTLV-I transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. Similar studies have not been performed in humans. Freeze-thawing of breast milk is an effective way to reduce transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bottle-fed infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since 3 to 4 percent of bottle-fed infants born to HTLV-I infected mothers are HTLV-I seropositive [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/62\">",
"     62",
"    </a>",
"    ], transmission to children by routes other than breast feeding is possible. The period of risk appears to be greatest within the first two years of life. A prospective study of 154 bottle-fed infants born to seropositive mothers showed that the risk of infection was 0.6 percent at one year and 4.6 percent at two years, with no new acquisition of infection for the 10 years following this two-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The route of this transmission remains uncertain. HTLV-I provirus can be identified in cord blood and maternal saliva, but convincing evidence that either of these account for infection in the absence of breast feeding is lacking. In a prospective study, all seven children found to have HTLV-I proviral DNA in cord blood were HTLV-I seronegative at one to two years [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/70\">",
"     70",
"    </a>",
"    ]. One reason for this may be that cord blood provirus is frequently defective and unable to establish infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/71\">",
"     71",
"    </a>",
"    ]. Saliva and mouthwash specimens have also been shown to harbor proviral DNA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. However, lymphocytes are infrequent in saliva, and saliva itself frequently contains HTLV-I antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/75\">",
"     75",
"    </a>",
"    ] and can inhibit cell transmission in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sexual transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;HTLV-I can be transmitted via sexual intercourse, but the frequency of this means of transmission has been difficult to define. The prevalence of antibodies to HTLV-I in female sex workers differs by location, ranging from 3.2 to 21.8 percent in Kinshasa, Zaire and Callao, Peru, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, male to female transmission is more efficient than the reverse. As an example, the infection rate was considerably higher in the seronegative heterosexual partner when a man was the HTLV-I positive partner compared to a woman (4.9 versus 1.2 per 100 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/79\">",
"     79",
"    </a>",
"    ]. The presence of coexisting genital ulceration and cervicitis is associated with an increased risk of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/51,78\">",
"     51,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transmission via sexual intercourse also appears to be related to viral or proviral DNA load [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/24,80\">",
"     24,80",
"    </a>",
"    ]. In one study, men who transmitted the virus to their heterosexual partners had significantly higher geometric mean viral loads than non-transmitters [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study of 2655 Peruvian men who have sex with men (MSM), HTLV-1 infection was detected in 1.8 percent of subjects, while HIV infection was detected in 12.4 percent; 7 percent of HIV-infected men had HTLV coinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of infected cells, but not plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/76\">",
"     76",
"    </a>",
"    ], is an efficient means of HTLV-I transmission. The estimated probability of seroconversion by this route is 40 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], with a mean time to seroconversion of 51 days [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/83\">",
"     83",
"    </a>",
"    ]. Accordingly, for countries with high HTLV-I seroprevalence rates, routine screening of blood donations for this virus is an effective way of reducing transfusion-related infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The seroprevalence of HTLV-I in blood donors is generally much lower than in the general population (9.6 per 100,000 person years in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/85\">",
"     85",
"    </a>",
"    ], 32 per 100,000 in Taiwan [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/86\">",
"     86",
"    </a>",
"    ]), since patients at risk of bloodborne disease are usually excluded from donating. Where screening occurs, overall risks of transmission are low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Tissue donation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The likelihood of tissue donors having viremia due to HTLV (as well as hepatitis B, hepatitis C, and HIV) was evaluated in 11,391 tissue donors to five tissue banks in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/89\">",
"     89",
"    </a>",
"    ]. The estimated probability of HTLV viremia at the time of donation that would be undetected by screening with current serologic methods was 1 in 128,000 for HTLV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Injection drug use",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of injection drug use (IDU) as a route of transmission varies widely among countries and is dependent upon the baseline seroprevalence in the region. Certain areas (eg, Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/90\">",
"     90",
"    </a>",
"    ], Eastern Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/91\">",
"     91",
"    </a>",
"    ], Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/92\">",
"     92",
"    </a>",
"    ]) have low seroprevalences among drug users. Higher rates have been reported in areas with a high seroprevalence in the general population (eg, 20 to 40 percent in one Brazilian study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5897/abstract/93\">",
"     93",
"    </a>",
"    ]). Many studies fail to distinguish between HTLV-I and HTLV-II infection, although those that do suggest that HTLV-I is consistently less prevalent than HTLV-II among IDUs in Western Europe and the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29033435\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human T-lymphotropic virus (HTLV-I) is estimated to infect 10 to 20 million people worldwide. This virus is the causative agent of two typically fatal diseases: adult T cell leukemia-lymphoma and HTLV-I-associated myelopathy, which is also known as tropical spastic paraparesis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lower levels of viral DNA within peripheral blood mononuclear cells (PBMCs) correlate with asymptomatic infection while higher levels correlate with HTLV-associated diseases, such as HTLV-I-associated myelopathy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Proviral load determination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Like human immunodeficiency virus type 1 (HIV-1), HTLV-I infects CD4 T-cells; however, unlike HIV-1, which causes T-cell death, HTLV-I leads to cellular proliferation and transformation and disease states such as adult T cell leukemia-lymphoma. These two viruses also differ in viral replication rates and genetic stability; HIV is associated with high levels of viremia and genetic heterogeneity, while HTLV-I is associated with a low replication rate and genetic stability of its viral progeny. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HTLV-I is primarily transmitted by breast feeding, although spread via blood transfusion, sharing of needles, and sexual intercourse also occurs. Measures to reduce the risk of transmission exist for each of these routes. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Epidemiology and transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The likelihood of tissue donors having viremia due to HTLV-I is low in the United States. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Tissue donation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/1\">",
"      Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77:7415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/2\">",
"      de Th&eacute; G, Bomford R. An HTLV-I vaccine: why, how, for whom? AIDS Res Hum Retroviruses 1993; 9:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/3\">",
"      Hinuma Y, Nagata K, Hanaoka M, et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc Natl Acad Sci U S A 1981; 78:6476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/4\">",
"      Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/5\">",
"      Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci U S A 1982; 79:2031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/6\">",
"      Osame M, Usuku K, Izumo S, et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1986; 1:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/7\">",
"      Gessain A, Barin F, Vernant JC, et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 1985; 2:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/8\">",
"      Mahieux R, Gessain A. The human HTLV-3 and HTLV-4 retroviruses: new members of the HTLV family. Pathol Biol (Paris) 2009; 57:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/9\">",
"      Seiki M, Hattori S, Hirayama Y, Yoshida M. Human adult T-cell leukemia virus: complete nucleotide sequence of the provirus genome integrated in leukemia cell DNA. Proc Natl Acad Sci U S A 1983; 80:3618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/10\">",
"      Gaudray G, Gachon F, Basbous J, et al. The complementary strand of the human T-cell leukemia virus type 1 RNA genome encodes a bZIP transcription factor that down-regulates viral transcription. J Virol 2002; 76:12813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/11\">",
"      Ghez D, Lepelletier Y, Lambert S, et al. Neuropilin-1 is involved in human T-cell lymphotropic virus type 1 entry. J Virol 2006; 80:6844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/12\">",
"      Jones KS, Petrow-Sadowski C, Huang YK, et al. Cell-free HTLV-1 infects dendritic cells leading to transmission and transformation of CD4(+) T cells. Nat Med 2008; 14:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/13\">",
"      Coskun AK, Sutton RE. Expression of glucose transporter 1 confers susceptibility to human T-cell leukemia virus envelope-mediated fusion. J Virol 2005; 79:4150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/14\">",
"      Manel N, Kim FJ, Kinet S, et al. The ubiquitous glucose transporter GLUT-1 is a receptor for HTLV. Cell 2003; 115:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/15\">",
"      Takenouchi N, Jones KS, Lisinski I, et al. GLUT1 is not the primary binding receptor but is associated with cell-to-cell transmission of human T-cell leukemia virus type 1. J Virol 2007; 81:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/16\">",
"      Kakuda K, Ikematsu H, Chong WL, et al. Molecular epidemiology of human T lymphotropic virus type 1 transmission in Okinawa, Japan. Am J Trop Med Hyg 2002; 66:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/17\">",
"      Felber BK, Paskalis H, Kleinman-Ewing C, et al. The pX protein of HTLV-I is a transcriptional activator of its long terminal repeats. Science 1985; 229:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/18\">",
"      Sodroski JG, Rosen CA, Haseltine WA. Trans-acting transcriptional activation of the long terminal repeat of human T lymphotropic viruses in infected cells. Science 1984; 225:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/19\">",
"      Uchiyama T. Human T cell leukemia virus type I (HTLV-I) and human diseases. Annu Rev Immunol 1997; 15:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/20\">",
"      Taylor GP, Tosswill JH, Matutes E, et al. Prospective study of HTLV-I infection in an initially asymptomatic cohort. J Acquir Immune Defic Syndr 1999; 22:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/21\">",
"      Etoh K, Yamaguchi K, Tokudome S, et al. Rapid quantification of HTLV-I provirus load: detection of monoclonal proliferation of HTLV-I-infected cells among blood donors. Int J Cancer 1999; 81:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/22\">",
"      Manns A, Miley WJ, Wilks RJ, et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 1999; 180:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/23\">",
"      Kwaan N, Lee TH, Chafets DM, et al. Long-term variations in human T lymphotropic virus (HTLV)-I and HTLV-II proviral loads and association with clinical data. J Infect Dis 2006; 194:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/24\">",
"      Iga M, Okayama A, Stuver S, et al. Genetic evidence of transmission of human T cell lymphotropic virus type 1 between spouses. J Infect Dis 2002; 185:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/25\">",
"      Jeffery KJ, Siddiqui AA, Bunce M, et al. The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol 2000; 165:7278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/26\">",
"      Grassmann R, Dengler C, M&uuml;ller-Fleckenstein I, et al. Transformation to continuous growth of primary human T lymphocytes by human T-cell leukemia virus type I X-region genes transduced by a Herpesvirus saimiri vector. Proc Natl Acad Sci U S A 1989; 86:3351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/27\">",
"      Grassmann R, Berchtold S, Radant I, et al. Role of human T-cell leukemia virus type 1 X region proteins in immortalization of primary human lymphocytes in culture. J Virol 1992; 66:4570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/28\">",
"      Smith MR, Greene WC. Type I human T cell leukemia virus tax protein transforms rat fibroblasts through the cyclic adenosine monophosphate response element binding protein/activating transcription factor pathway. J Clin Invest 1991; 88:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/29\">",
"      Tanaka A, Takahashi C, Yamaoka S, et al. Oncogenic transformation by the tax gene of human T-cell leukemia virus type I in vitro. Proc Natl Acad Sci U S A 1990; 87:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/30\">",
"      Seiki M, Eddy R, Shows TB, Yoshida M. Nonspecific integration of the HTLV provirus genome into adult T-cell leukaemia cells. Nature 1984; 309:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/31\">",
"      Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Annu Rev Immunol 2001; 19:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/32\">",
"      Jeang KT, Widen SG, Semmes OJ 4th, Wilson SH. HTLV-I trans-activator protein, tax, is a trans-repressor of the human beta-polymerase gene. Science 1990; 247:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/33\">",
"      Jin DY, Spencer F, Jeang KT. Human T cell leukemia virus type 1 oncoprotein Tax targets the human mitotic checkpoint protein MAD1. Cell 1998; 93:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/34\">",
"      Satou Y, Yasunaga J, Yoshida M, Matsuoka M. HTLV-I basic leucine zipper factor gene mRNA supports proliferation of adult T cell leukemia cells. Proc Natl Acad Sci U S A 2006; 103:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/35\">",
"      Zhao T, Yasunaga J, Satou Y, et al. Human T-cell leukemia virus type 1 bZIP factor selectively suppresses the classical pathway of NF-kappaB. Blood 2009; 113:2755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/36\">",
"      Arnold J, Zimmerman B, Li M, et al. Human T-cell leukemia virus type-1 antisense-encoded gene, Hbz, promotes T-lymphocyte proliferation. Blood 2008; 112:3788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/37\">",
"      Manns A, Murphy EL, Wilks R, et al. Detection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients. Blood 1991; 77:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/38\">",
"      Kira J, Koyanagi Y, Yamada T, et al. Increased HTLV-I proviral DNA in HTLV-I-associated myelopathy: a quantitative polymerase chain reaction study. Ann Neurol 1991; 29:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/39\">",
"      Kamihira S, Toriya K, Amagasaki T, et al. Antibodies against p40tax gene product of human T-lymphotropic virus type-I (HTLV-I) under various conditions of HTLV-I infection. Jpn J Cancer Res 1989; 80:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/40\">",
"      Kannagi M, Harada S, Maruyama I, et al. Predominant recognition of human T cell leukemia virus type I (HTLV-I) pX gene products by human CD8+ cytotoxic T cells directed against HTLV-I-infected cells. Int Immunol 1991; 3:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/41\">",
"      Parker CE, Nightingale S, Taylor GP, et al. Circulating anti-Tax cytotoxic T lymphocytes from human T-cell leukemia virus type I-infected people, with and without tropical spastic paraparesis, recognize multiple epitopes simultaneously. J Virol 1994; 68:2860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/42\">",
"      Niewiesk S, Daenke S, Parker CE, et al. Naturally occurring variants of human T-cell leukemia virus type I Tax protein impair its recognition by cytotoxic T lymphocytes and the transactivation function of Tax. J Virol 1995; 69:2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/43\">",
"      Jacobson S, Reuben JS, Streilein RD, Palker TJ. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1. J Immunol 1991; 146:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/44\">",
"      Arnulf B, Thorel M, Poirot Y, et al. Loss of the ex vivo but not the reinducible CD8+ T-cell response to Tax in human T-cell leukemia virus type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 2004; 18:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/45\">",
"      Wodarz D, Hall SE, Usuku K, et al. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus type 1 and human T-cell leukaemia virus type 1. Proc Biol Sci 2001; 268:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/46\">",
"      Sabouri AH, Usuku K, Hayashi D, et al. Impaired function of human T-lymphotropic virus type 1 (HTLV-1)-specific CD8+ T cells in HTLV-1-associated neurologic disease. Blood 2008; 112:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/47\">",
"      Blattner WA, Saxinger C, Riedel D, et al. A study of HTLV-I and its associated risk factors in Trinidad and Tobago. J Acquir Immune Defic Syndr 1990; 3:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/48\">",
"      Mueller N, Okayama A, Stuver S, Tachibana N. Findings from the Miyazaki Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13 Suppl 1:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/49\">",
"      Murphy EL, Watanabe K, Nass CC, et al. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999; 180:1777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/50\">",
"      Taylor GP, Bod&eacute;us M, Courtois F, et al. The seroepidemiology of human T-lymphotropic viruses: types I and II in Europe: a prospective study of pregnant women. J Acquir Immune Defic Syndr 2005; 38:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/51\">",
"      Murphy EL, Figueroa JP, Gibbs WN, et al. Sexual transmission of human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 1989; 111:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/52\">",
"      Manns A, Hisada M, La Grenade L. Human T-lymphotropic virus type I infection. Lancet 1999; 353:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/53\">",
"      Gessain A, Gallo RC, Franchini G. Low degree of human T-cell leukemia/lymphoma virus type I genetic drift in vivo as a means of monitoring viral transmission and movement of ancient human populations. J Virol 1992; 66:2288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/54\">",
"      Nerurkar VR, Song KJ, Saitou N, et al. Interfamilial and intrafamilial genomic diversity and molecular phylogeny of human T-cell lymphotropic virus type I from Papua New Guinea and the Solomon Islands. Virology 1993; 196:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/55\">",
"      Liu HF, Vandamme AM, Kazadi K, et al. Familial transmission and minimal sequence variability of human T-lymphotropic virus type I (HTLV-I) in Zaire. AIDS Res Hum Retroviruses 1994; 10:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/56\">",
"      Biggar RJ, Ng J, Kim N, et al. Human leukocyte antigen concordance and the transmission risk via breast-feeding of human T cell lymphotropic virus type I. J Infect Dis 2006; 193:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/57\">",
"      Plancoulaine S, Gessain A, Tortevoye P, et al. A major susceptibility locus for HTLV-1 infection in childhood maps to chromosome 6q27. Hum Mol Genet 2006; 15:3306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/58\">",
"      Kinoshita K, Hino S, Amagaski T, et al. Demonstration of adult T-cell leukemia virus antigen in milk from three sero-positive mothers. Gann 1984; 75:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/59\">",
"      Yamanouchi K, Kinoshita K, Moriuchi R, et al. Oral transmission of human T-cell leukemia virus type-I into a common marmoset (Callithrix jacchus) as an experimental model for milk-borne transmission. Jpn J Cancer Res 1985; 76:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/60\">",
"      Hirata M, Hayashi J, Noguchi A, et al. The effects of breastfeeding and presence of antibody to p40tax protein of human T cell lymphotropic virus type-I on mother to child transmission. Int J Epidemiol 1992; 21:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/61\">",
"      Tsuji Y, Doi H, Yamabe T, et al. Prevention of mother-to-child transmission of human T-lymphotropic virus type-I. Pediatrics 1990; 86:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/62\">",
"      Takahashi K, Takezaki T, Oki T, et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. The Mother-to-Child Transmission Study Group. Int J Cancer 1991; 49:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/63\">",
"      Takezaki T, Tajima K, Ito M, et al. Short-term breast-feeding may reduce the risk of vertical transmission of HTLV-I. The Tsushima ATL Study Group. Leukemia 1997; 11 Suppl 3:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/64\">",
"      Wiktor SZ, Pate EJ, Rosenberg PS, et al. Mother-to-child transmission of human T-cell lymphotropic virus type I associated with prolonged breast-feeding. J Hum Virol 1997; 1:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/65\">",
"      Li HC, Biggar RJ, Miley WJ, et al. Provirus load in breast milk and risk of mother-to-child transmission of human T lymphotropic virus type I. J Infect Dis 2004; 190:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/66\">",
"      Ando Y, Kakimoto K, Tanigawa T, et al. Effect of freeze-thawing breast milk on vertical HTLV-I transmission from seropositive mothers to children. Jpn J Cancer Res 1989; 80:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/67\">",
"      Miyoshi I, Takehara N, Sawada T, et al. Immunoglobulin prophylaxis against HTLV-I in a rabbit model. Leukemia 1992; 6 Suppl 1:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/68\">",
"      Sawada T, Iwahara Y, Ishii K, et al. Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits. J Infect Dis 1991; 164:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/69\">",
"      Ando Y, Matsumoto Y, Nakano S, et al. Long-term follow-up study of HTLV-I infection in bottle-fed children born to seropositive mothers. J Infect 2003; 46:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/70\">",
"      Katamine S, Moriuchi R, Yamamoto T, et al. HTLV-I proviral DNA in umbilical cord blood of babies born to carrier mothers. Lancet 1994; 343:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/71\">",
"      Kazi A, Miyata H, Kamahora T, et al. Deleted HTLV-1 provirus in cord-blood samples of babies born to HTLV-1-carrier mothers. Int J Cancer 1998; 77:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/72\">",
"      Achiron A, Pinhas-Hamiel O, Barak Y, et al. Detection of proviral human T-cell lymphotrophic virus type I DNA in mouthwash samples of HAM/TSP patients and HTLV-I carriers. Arch Virol 1996; 141:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/73\">",
"      Achiron A, Higuchi I, Takenouchi N, et al. Detection of HTLV type I provirus by in situ polymerase chain reaction in mouthwash mononuclear cells of HAM/TSP patients and HTLV type I carriers. AIDS Res Hum Retroviruses 1997; 13:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/74\">",
"      Miyoshi I, Sawada T, Iwahara Y, et al. Excretion of HTLV-I in saliva. JAMA 1992; 267:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/75\">",
"      Archibald D, Essex M, McLane MF, et al. Antibodies to HTLV-1 in saliva of seropositive individuals from Japan. Viral Immunol 1987; 1:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/76\">",
"      Yamamoto T, Terada K, Nishida N, et al. Inhibitory activity in saliva of cell-to-cell transmission of human T-cell lymphotropic virus type 1 in vitro: evaluation of saliva as an alternative source of transmission. J Clin Microbiol 1995; 33:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/77\">",
"      Wignall FS, Hyams KC, Phillips IA, et al. Sexual transmission of human T-lymphotropic virus type I in Peruvian prostitutes. J Med Virol 1992; 38:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/78\">",
"      Zunt JR, Dezzutti CS, Montano SM, et al. Cervical shedding of human T cell lymphotropic virus type I is associated with cervicitis. J Infect Dis 2002; 186:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/79\">",
"      Stuver SO, Tachibana N, Okayama A, et al. Heterosexual transmission of human T cell leukemia/lymphoma virus type I among married couples in southwestern Japan: an initial report from the Miyazaki Cohort Study. J Infect Dis 1993; 167:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/80\">",
"      Kaplan JE, Khabbaz RF, Murphy EL, et al. Male-to-female transmission of human T-cell lymphotropic virus types I and II: association with viral load. The Retrovirus Epidemiology Donor Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 12:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/81\">",
"      La Rosa AM, Zunt JR, Peinado J, et al. Retroviral infection in Peruvian men who have sex with men. Clin Infect Dis 2009; 49:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/82\">",
"      Chen YC, Wang CH, Su IJ, et al. Infection of human T-cell leukemia virus type I and development of human T-cell leukemia lymphoma in patients with hematologic neoplasms: a possible linkage to blood transfusion. Blood 1989; 74:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/83\">",
"      Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T cell leukemia virus by blood transfusion: seroconversion in recipients. Vox Sang 1984; 46:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/84\">",
"      Kamihira S, Nakasima S, Oyakawa Y, et al. Transmission of human T cell lymphotropic virus type I by blood transfusion before and after mass screening of sera from seropositive donors. Vox Sang 1987; 52:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/85\">",
"      Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/86\">",
"      Lu SC, Kao CL, Chin LT, et al. Seroprevalence and demographic characteristics of HTLV-I among blood donors in Taiwan: 1996-1999. Int J Hematol 2001; 74:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/87\">",
"      Chiavetta JA, Escobar M, Newman A, et al. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003; 169:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/88\">",
"      Pillonel J, Laperche S, Saura C, et al. Trends in residual risk of transfusion-transmitted viral infections in France between 1992 and 2000. Transfusion 2002; 42:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/89\">",
"      Zou S, Dodd RY, Stramer SL, et al. Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004; 351:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/90\">",
"      Giuliani M, Rezza G, Lepri AC, et al. Risk factors for HTLV-I and II in individuals attending a clinic for sexually transmitted diseases. Sex Transm Dis 2000; 27:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/91\">",
"      Poljak M, Bednarik J, Rednak K, et al. Seroprevalence of human T cell leukaemia/lymphoma virus type I (HTLV-I) in pregnant women, patients attending venereological outpatient services and intravenous drug users from Slovenia. Folia Biol (Praha) 1998; 44:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/92\">",
"      Urwijitaroon Y, Barusrux S, Puapairoj C, et al. Seroepidemiology of HTLV-I infection in northeast Thailand: a four year surveillance. J Med Assoc Thai 1997; 80 Suppl 1:S102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5897/abstract/93\">",
"      Dourado I, Andrade T, Carpenter CL, Galv&atilde;o-Castro B. Risk factors for human T cell lymphotropic virus type I among injecting drug users in northeast Brazil: possibly greater efficiency of male to female transmission. Mem Inst Oswaldo Cruz 1999; 94:13.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8316 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5897=[""].join("\n");
var outline_f5_48_5897=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29033435\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      VIROLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Cell entry and replication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proviral load determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cellular transformation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Immunologic control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY AND TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Breast feeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bottle-fed infants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sexual transmission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Tissue donation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Injection drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29033435\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/8316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/8316|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/1/32795\" title=\"figure 1\">",
"      HTLV-I genome organization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/54/40808?source=related_link\">",
"      Human T-lymphotropic virus type I: Disease associations, diagnosis, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_48_5898="T wave (repolarization) alternans: Clinical aspects";
var content_f5_48_5898=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   T wave (repolarization) alternans: Clinical aspects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5898/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5898/contributors\">",
"     Sanjiv M Narayan, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5898/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5898/contributors\">",
"     Ary L Goldberger, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/48/5898/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/48/5898/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/48/5898/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical risk stratification for sudden cardiac death typically focuses on the presence of a reduced left ventricular ejection fraction and the presence of heart failure. However, these parameters identify only a minority of individuals who will die suddenly, and also identify others who will not suffer lethal ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. As a result, there is continued interest in additional electrophysiologic indices for risk prediction, of which one of the most promising remains T-wave alternans (TWA) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TWA refers to beat-to-beat variability in the timing or shape of T-waves on the surface electrocardiogram (ECG) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. TWA reflects temporal heterogeneity or dispersion in ventricular repolarization, which is an important mechanism underlying reentrant arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Several studies suggest that TWA may add value to signal-averaged ECG, heart rate variability, and other indices. TWA is approved by the United States Food and Drug Administration (FDA) for noninvasively predicting the risk for life-threatening ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical utility of TWA will be reviewed here. The technical aspects and methods for analyzing TWA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9800?source=see_link\">",
"     \"T wave (repolarization) alternans: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK STRATIFICATION FOR SCD",
"    </span>",
"    &nbsp;&mdash;&nbsp;TWA is primarily used as a tool for the risk stratification for sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/6\">",
"     6",
"    </a>",
"    ]. Most of the focus of such efforts has been on patients with prior myocardial infarction, reduced left ventricular (LV) ejection fraction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptomatic heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. More recently, TWA has been studied in more diverse populations.",
"   </p>",
"   <p>",
"    Historically, studies of TWA may be divided into three phases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Studies showing that TWA is concordant with the results from programmed ventricular stimulation at electrophysiologic (EP) testing.",
"     </li>",
"     <li>",
"      Studies showing that TWA predicts spontaneous ventricular arrhythmias in patients with LV dysfunction, with or without coronary heart disease (CHD) and with or without symptomatic heart failure.",
"     </li>",
"     <li>",
"      Studies evaluating TWA for predicting spontaneous ventricular arrhythmias in other patient populations, including those with left ventricular hypertrophy or with end-stage renal disease. Although TWA is increasingly applied to wider populations, Bayes' theorem requires that the pretest probability for each population is considered when interpreting the results. This is an important issue since the pathophysiologic link between TWA and arrhythmias is less clear in patients without the substrates for reentry (ie, patients without left ventricular dysfunction, structural disease, or known electrophysiologic heterogeneities).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are two predominant methods for determining TWA, the spectral approach and the newer modified moving average approach. These methods are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9800?source=see_link&amp;anchor=H3#H3\">",
"     \"T wave (repolarization) alternans: Technical aspects\", section on 'Methods for analysis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indeterminate results",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most data have been accrued using the spectral approach, approximately 20 to 40 percent of such TWA alternans tests are classified as \"indeterminate,\" in that the results of the test do not demonstrate or exclude the presence of TWA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. In the early literature, tests were considered indeterminate based upon patient factors (eg, frequent ventricular ectopy or inability to achieve the target heart rate), as well as technical factors (eg, significant artifact on the electrocardiogram). Currently, it is recommended that patients be immediately retested if results are indeterminate.",
"   </p>",
"   <p>",
"    The high incidence of indeterminate results has been a challenge in the clinical application of TWA by the spectral method. Some investigators have included indeterminate results with abnormal studies, under the category \"non-negative.\" This approach is supported by observations that outcomes are similar in patients with abnormal TWA and those with indeterminate studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], if the indeterminacy is caused by patient-related rather than technical factors.",
"   </p>",
"   <p>",
"    The causes and prognostic significance of indeterminate results were directly assessed in a series of 549 patients with ischemic and nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/13\">",
"     13",
"    </a>",
"    ]. The following results were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      191 patients (35 percent) had an indeterminate result.",
"     </li>",
"     <li>",
"      Among the indeterminate results, 51 percent were due to the inability to achieve a diagnostic heart rate (105",
"      <span class=\"nowrap\">",
"       beats/min),",
"      </span>",
"      and 32 percent were due to ventricular ectopy, while only 6 percent were due to technical factors.",
"     </li>",
"     <li>",
"      The two-year event rates for the combined endpoint of death or sustained ventricular arrhythmia for patients with indeterminate, positive, and negative TWA results were 12.3, 17.8, and 2.4 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, indeterminate results were common, were usually due to patient factors, and predicted death and ventricular arrhythmia rates similar to those of positive results. These observations support the premise that TWA testing is most useful for identifying patients at a low risk of ventricular arrhythmias via its negative results. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Identifying a low-risk subgroup from identified high-risk patients'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Predicting inducible VT/VF at electrophysiology study",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to induce sustained ventricular tachycardia (VT) and, in certain circumstances, ventricular fibrillation (VF) during electrophysiology (EP) study has long been used to predict arrhythmic events in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/17\">",
"     17",
"    </a>",
"    ]. As a result, most initial studies of TWA used inducible VT and VF as surrogate end points for arrhythmic risk. These studies demonstrated that the presence of TWA during atrial or ventricular pacing or exercise correlated with the ability to induce ventricular arrhythmias in patients undergoing EP testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/2,11,18-20\">",
"     2,11,18-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A seminal early study included 83 patients at high risk for ventricular arrhythmias who were referred for EP study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/2\">",
"     2",
"    </a>",
"    ]. TWA during atrial pacing had a sensitivity and specificity for inducible VT or VF of 81 and 84 percent, respectively. Similar values (88 and 78 percent) were noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/20\">",
"     20",
"    </a>",
"    ]. A later and much larger study included 313 patients referred for EP study for syncope, ventricular tachycardia, SCD, or, in 31 percent, supraventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/11\">",
"     11",
"    </a>",
"    ]. The sensitivity and specificity of TWA during exercise for the prediction of inducible VT or VF in that study was 78 and 73 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Predicting clinical arrhythmic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Having established a concordance between TWA and the results from EP testing, studies moved on to focus on the utility of TWA for predicting spontaneous arrhythmic events [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/2,10,11\">",
"     2,10,11",
"    </a>",
"    ]. The value of TWA, as with any diagnostic test, depends on the patient population being studied. The role of TWA in various populations is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Unselected populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have examined the predictive value of TWA measured by the modified moving average method in patients undergoing exercise stress testing and not identified as being at high risk for ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the largest study of 3598 patients undergoing stress testing, the risk of cardiovascular mortality and sudden cardiac death increased progressively with each 20-microvolt increase in TWA in lead V5 (hazard ratios 1.5 [95% CI 1.2 to 2.1] and 1.6 [95% CI 1.0 to 2.4], respectively, for each 20-microvolt increase) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a smaller study of nearly 2000 patients undergoing stress testing from the same population, abnormal TWA and heart rate recovery were assessed [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/22\">",
"       22",
"      </a>",
"      ]. Both abnormal TWA and abnormal TWA combined with abnormal heart rate recovery were associated with an increased risk for cardiovascular death (relative risk 5.0 [95% CI 2.1 to 12.1] and 6.1 [95% CI 2.8 to 13.2], respectively). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=see_link&amp;anchor=H5#H5\">",
"       \"Exercise ECG testing to determine prognosis of coronary heart disease\", section on 'Heart rate recovery after exercise'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3515198\">",
"    <span class=\"h3\">",
"     Patients at high risk for ventricular arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one early report, TWA-positive patients had a significantly lower arrhythmia-free survival at 20 months than those testing TWA-negative (19 versus 94 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar results were reported in other series, but much of this initial data was derived from consecutive patients referred for EP study with a variety of diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Due to the heterogeneity of these populations, it is difficult to generalize the predictive accuracy of TWA from these studies. This limitation was highlighted in a subsequent report of 108 high-risk patients, in which the specificity of TWA for arrhythmic events was only 43 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2006 meta-analysis included 2608 patients from 19 prospective studies of TWA (measured spectrally) in a variety of clinical settings: seven studies of nonischemic heart failure, three studies of unspecified heart failure, two studies of ischemic heart failure, three studies of post-myocardial infarction (MI) patients, one study of ICD recipients, one study of athletic heart patients, and two studies of healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/9\">",
"     9",
"    </a>",
"    ]. The following findings were reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The overall positive and negative predictive values of TWA for ventricular arrhythmic events were 19 and 97 percent.",
"     </li>",
"     <li>",
"      Positive predictive value was lower and negative predictive value was slightly higher in post-MI patients (6 and 99 percent, respectively). However, the patients in the post-MI studies had average LVEFs between 45 and 56 percent.",
"     </li>",
"     <li>",
"      Predictive accuracy of TWA was not significantly different in ischemic and nonischemic heart failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Patients with CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with coronary heart disease (CHD) with or without prior myocardial infarction (MI) represent the population most extensively studied for ventricular arrhythmia risk stratification using TWA testing. Although the reports described above included such patients, as many as 31 percent underwent EPS for indications unrelated to CHD or ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Further studies limited to CHD and post-MI patients clarified the role of TWA in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/14,26,27\">",
"     14,26,27",
"    </a>",
"    ]. A general discussion of risk stratification for arrhythmic death after MI is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The value of TWA and late potentials on signal averaged electrocardiogram (SAECG) in predicting clinical events was evaluated in a prospective study of 102 patients with a recent (7 to 30 days) MI; 49 percent had TWA and 21 percent had late potentials [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/26\">",
"       26",
"      </a>",
"      ]. After a follow-up of 13 months, the risk of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF) was increased in patients with TWA, particularly those who also had late potentials (",
"      <a class=\"graphic graphic_figure graphicRef71874 \" href=\"UTD.htm?22/26/22957\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef51831 \" href=\"UTD.htm?20/62/21486\">",
"       figure 2",
"      </a>",
"      ). The sensitivity and specificity of TWA for predicting arrhythmic events were 93 and 59 percent, respectively.",
"     </li>",
"     <li>",
"      In a larger multicenter analysis of 850 consecutive MI survivors, TWA was assessed at 2 to 10 weeks in 701 patients, and from several months to two years in 149 [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/14\">",
"       14",
"      </a>",
"      ]. TWA was positive in 302 patients (36 percent), negative in 437 (52 percent) and indeterminate in 95 (12 percent). At a mean follow-up of 25 months, 67 patients (8 percent) had sudden cardiac death, resuscitated VF, or VT. Among 11 variables evaluated for predictive value, only two significantly predicted death or resuscitated VF on multivariate analysis: TWA (relative risk [RR] 5.9) and a left ventricular ejection fraction (LVEF) &lt;40 percent (RR 4.4). The sensitivity and specificity of TWA for predicting arrhythmic events were 92 and 61 percent. TWA was also predictive of arrhythmic events in a larger series limited to post-MI patients with a preserved ejection fraction (LVEF &ge;40 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The independent prognostic value of TWA was assessed in a large observational study of 768 high-risk patients with ischemic cardiomyopathy [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/15\">",
"       15",
"      </a>",
"      ]. Over 80 percent had a prior MI, the average LVEF was 27 percent, and 51 percent had an ICD. All patients underwent TWA testing, and the 67 percent with abnormal or indeterminate results (referred to as \"non-negative\") were compared to those with a negative TWA study. Over a mean follow-up of 18 months, a non-negative TWA result was associated with increased all-cause and arrhythmic mortality (adjusted HR 2.24 and 2.29, respectively, compared to patients with a negative TWA). These results provide evidence that TWA retains independent prognostic value when applied to a high-risk population.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of TWA for stratifying arrhythmic risk post-MI probably depends upon the time after MI at which the study is obtained. In particular, assessment for TWA may not be of value when performed at hospital discharge. This was suggested in a report of 379 post-MI patients in whom TWA was assessed during a symptom-limited exercise test prior to discharge; TWA was present in 56 (15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/27\">",
"     27",
"    </a>",
"    ]. At 14 month follow-up, 26 patients died, none of whom had TWA. Measurement of TWA within the first month post-MI was also not useful for predicting SCD in the REFINE study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Combining TWA with other indices'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3515216\">",
"    <span class=\"h4\">",
"     Diabetic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has long been understood that diabetic patients have the equivalent of coronary disease, and their risk for sudden cardiac death (SCD) is being increasingly well characterized. Recent studies suggest that the risk for SCD from diabetes is equivalent to the risk conferred by LV systolic dysfunction, and that these risks are additive if both present [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/29\">",
"     29",
"    </a>",
"    ]. It has been suggested in several recent trials that TWA (measured spectrally) may effectively stratify SCA risk in diabetics, although other studies caution that TWA abnormalities in this population actually indicate poor glycemic control [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Further studies are needed to define the role of TWA testing in diabetics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h4\">",
"     LV systolic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular systolic dysfunction is the primary mode of risk stratification for ventricular arrhythmias. Systolic dysfunction (LVEF &le;40 percent) identifies patients with ischemic and nonischemic cardiomyopathy who are at risk for serious ventricular tachyarrhythmias and SCD. The data supporting these conclusions are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H7#H7\">",
"     \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'LV dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link\">",
"     \"Ventricular arrhythmias in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Multivariate analyses have shown that TWA predicts ventricular arrhythmias independent of reduced LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/2,11,14,26\">",
"     2,11,14,26",
"    </a>",
"    ], albeit in varying populations. In a series of 850 post-MI patients, the sensitivity and specificity of an LVEF &lt;40 percent for ventricular tachyarrhythmias were 56 and 83 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/14\">",
"     14",
"    </a>",
"    ]. Sensitivity and specificity were not significantly different (52 and 92 percent) in the smaller subset of patients who had both a low LVEF and TWA.",
"   </p>",
"   <p>",
"    The Alternans before Cardioverter-Defibrillator (ABCD) trial compared the effectiveness of ICD implantation guided either by a positive T-wave alternans test or by an EP study in 566 patients with coronary disease and reduced systolic function (LVEF &lt;40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/32\">",
"     32",
"    </a>",
"    ]. TWA guided therapy achieved one-year positive (9 percent) and negative (95 percent) predictive values comparable to those from EPS guided therapy (11 percent and 95 percent, respectively). Arrhythmic event rates were significantly higher in patients with a positive TWA (hazard ratio 2.1) or positive EPS (hazard ratio 2.4), although with positive predictive values of around 10 percent. Moreover, event rates in patients with negative TWA and EPS were lower than in those with two positive tests (2 percent versus 12 percent). The authors concluded that ICD implantation was equally effective whether guided by noninvasive MTWA or invasive EPS at one year, and complementary when both tests were combined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h4\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of heart failure (HF) predicts worse outcomes independent of LV function and TWA predicts arrhythmic events in patients with HF [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/33\">",
"     33",
"    </a>",
"    ]. The prognostic value of TWA was illustrated in a series of 107 patients with NYHA class II or III HF (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), an LVEF &lt;45 percent, and no history of sustained ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/34\">",
"     34",
"    </a>",
"    ]. TWA assessed during exercise was present in 49 percent and absent in 33 percent; 22 percent had an indeterminate study. At 14 month follow-up, patients with TWA had a significantly higher arrhythmic event rate than those with an indeterminate test or no TWA (21, 9, and 0 percent, respectively). None of the other predictors of arrhythmia risk (LVEF, baroreceptor sensitivity, signal-averaged ECG, presence of nonsustained ventricular tachycardia, and conventional heart rate variability) significantly correlated with arrhythmic events.",
"   </p>",
"   <p>",
"    The ALPHA trial tested the prognostic utility of TWA for predicting the combined endpoint of cardiac death and life-threatening arrhythmias in patients with nonischemic dilated cardiomyopathy (LVEF &lt;40 percent) and NYHA class II and III heart failure over 18 to 24 months of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/20\">",
"     20",
"    </a>",
"    ]. TWA retained a high negative predictive value for the combined endpoint, although the overall event rate of the population was also very low [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Widened QRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mortality for patients with systolic heart failure is increased when the QRS duration is &ge;120 msec, and such patients are increasingly being treated with cardiac resynchronization therapy. Similarly, mortality in patients with an acute MI is increased in the presence of left bundle branch block. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=see_link&amp;anchor=H16#H16\">",
"     \"Conduction abnormalities after myocardial infarction\", section on 'Mortality and heart blocks'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of TWA for risk stratification in patients with QRS widening remains unclear. TWA was less predictive of arrhythmias and mortality in such patients in two reports, although TWA retained predictive value in the presence of a wide QRS complex in others, with and without pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/25,36-38\">",
"     25,36-38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     Identifying a low-risk subgroup from identified high-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expanding indications for implantable cardioverter-defibrillator (ICD) implantation pose clinical and economic challenges. As a result, it would be useful to develop refined risk stratification tools that identify patients who may not require ICD therapy from within a high-risk population that generally meets indications for ICD placement.",
"   </p>",
"   <p>",
"    In particular, there is interest in further risk stratification of patients who meet criteria for ICD therapy based upon MADIT II (LVEF &le;30 percent due to a prior MI) and SCD-HeFT (LVEF &le;35 percent due to any cause with associated NYHA class II or III heart failure) criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Although each of these trials demonstrated mortality benefit with ICD therapy in their respective populations, the absolute benefit was lower than that seen in the earlier MUSTT and MADIT I trials, suggesting that subsets of patients with lower individual risk are included within the population encompassed by MADIT II and SCD-HeFT inclusion criteria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=see_link&amp;anchor=H8#H8\">",
"     \"Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction\", section on 'ICD trials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data supporting the utility of TWA for this purpose include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A post hoc analysis of two prospective studies included 129 patients meeting MADIT II criteria who underwent TWA testing [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/41\">",
"       41",
"      </a>",
"      ]. Over a mean follow-up of 17 months, there was significant increase in sudden cardiac death (SCD) in patients with TWA (15.6 versus 0 percent without TWA). The absence of SCD in patients with a negative TWA study supports the hypothesis that this test may select low-risk patients from within an otherwise high-risk cohort.",
"     </li>",
"     <li>",
"      In a subset of patients from a prospective multicenter trial of TWA, among 177 patients who met MADIT II indications for ICD placement, 32 percent had a normal TWA study [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. At an average follow-up of 20 months, total mortality was lower in patients with a negative TWA (3.8 versus 17.8 percent in patients with an abnormal or indeterminate TWA, HR = 4.8).",
"     </li>",
"     <li>",
"      In a prospective cohort study of 768 patients with an ischemic cardiomyopathy (LVEF &le;35 percent) and no history of sustained ventricular arrhythmias, only the subset of patients with a non-negative (ie, abnormal or indeterminate) TWA study derived survival benefit from ICD placement [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another report using a Markov model in patients meeting MADIT II criteria, limiting ICD therapy to those who had an abnormal or indeterminate TWA study improved the cost-effectiveness of ICD therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H21#H21\">",
"     \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'Cost-effectiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The value of TWA for predicting events in patients with reduced ejection fraction has been questioned. This is illustrated by the following two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Master study was a prospective observational cohort study that evaluated the correlation between TWA testing and events rates in patients receiving an ICD for routine indications. TWA failed to predict the primary endpoint of arrhythmic events, although it did predict total mortality [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/45\">",
"       45",
"      </a>",
"      ]. This conclusion may have been limited by the fact that ICD event rates considerably overestimate the incidence of sudden cardiac arrest, since many ICD-detected events may have been self-limiting.",
"     </li>",
"     <li>",
"      The TWA substudy of the Sudden Cardiac Arrest in Heart Failure trial (SCD-HeFT) also showed that TWA failed to predict arrhythmic events in a subset of 490 patients from the parent trial [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/46\">",
"       46",
"      </a>",
"      ]. This conclusion may also have been limited by the dependence upon ICD endpoints (that are known to overestimate the true incidence of SCD), and by a very high rate of indeterminate TWA tests [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/47\">",
"       47",
"      </a>",
"      ]. In addition, the late incidence of arrhythmic events (typically after 1 year) reduced the event rate over the entire follow-up period, and may have reduced the power of TWA to predict events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the data from several studies are conflicting, the bulk of the evidence suggests that TWA predicts mortality from arrhythmic events. This is particularly true for studies that utilized clinical endpoints, but less true for studies that used ICD endpoints (with their tendency to overestimate the incidence of arrhythmic events) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/47\">",
"     47",
"    </a>",
"    ]. Further study is necessary to confirm the high negative predictive value of a normal TWA study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other patient populations",
"    </span>",
"    &nbsp;&mdash;&nbsp;TWA has also been evaluated in patients with nonischemic cardiomyopathy, long QT syndrome, and hypertrophic cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Nonischemic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;LV dysfunction due to causes other than coronary heart disease (CHD) may also carry a significant risk of sudden cardiac death (SCD) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/40\">",
"     40",
"    </a>",
"    ]. However, some risk stratification tools that are commonly used in CHD patients (eg, electrophysiology studies) are less predictive of arrhythmic events in nonischemic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have suggested that TWA predicts spontaneous ventricular arrhythmias and mortality in patients with LV dysfunction that is nonischemic or out of proportion to the extent of CHD. In a report of 137 patients with nonischemic cardiomyopathy, the presence of TWA predicted the combined endpoint of sudden death, resuscitated VF, or documented hemodynamically unstable VT [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protocol for assessing TWA is similar to that used in CHD populations, but performance characteristics of TWA may be different in nonischemic cardiomyopathy. As an example, there are conflicting data suggesting that TWA may best predict SCD at a lower onset heart rate (&lt;100",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    than is traditionally used (110",
"    <span class=\"nowrap\">",
"     beats/min)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. TWA tended to occur at a lower LVEF, and did not add additional risk stratification in multivariate analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Long QT syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some of the earliest reports of macroscopic TWA (ie, visually apparent on the conventional ECG) were in patients with the long QT syndrome (LQTS), and macroscopic TWA is part of the LQTS score that is most often used for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis of congenital long QT syndrome\", section on 'T wave alternans'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Macroscopic TWA is, however, an uncommon finding in congenital LQTS, occurring in only 1.2 percent of patients in a large series [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/51\">",
"     51",
"    </a>",
"    ]. Microvolt TWA is much more common, occurring in 44 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of TWA in LQTS patients may differ from that in patients with CHD, and the following mechanisms have been proposed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LQTS-associated TWA may represent early after depolarizations during phase 2 or phase 3 of the action potential that occur in alternate beats due to alternation in the duration of the plateau (phase 2) associated with increased susceptibility to this type of electrical instability [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/53\">",
"       53",
"      </a>",
"      ]. TWA of this nature has been shown to precede the onset of tachycardia-dependent torsades de pointes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=see_link\">",
"       \"Pathophysiology of the long QT syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a canine model of LQTS, TWA was induced by abrupt increases in heart rate [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/54\">",
"       54",
"      </a>",
"      ]. This was accompanied by significant increases in the dispersion of repolarization between epicardial and mid-myocardial regions compared to baseline. A similar mechanism has been observed in patients with congenital LQTS following abrupt heart rate acceleration, in which it was shown that successive beats may encroach upon refractoriness resulting from repolarization dispersion to cause functional conduction block and reentry [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Further study is required to delineate the mechanisms underlying TWA in LQTS, the predictive value of TWA for arrhythmic events in each genotypic form, and whether the disappearance of TWA is a surrogate for effective therapy such as beta blockers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=see_link&amp;anchor=H15#H15\">",
"     \"Prognosis and management of congenital long QT syndrome\", section on 'Beta blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data in small series suggest that TWA may predict arrhythmic events in patients with hypertrophic cardiomyopathy (HCM). In a series of 14 patients and 9 controls, TWA was present in five of seven patients with HCM deemed to be at high risk for an arrhythmia, compared to none of the low risk patients or control subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/56\">",
"     56",
"    </a>",
"    ]. All patients with sustained VT exhibited TWA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Comparison to other predictors of arrhythmic events",
"    </span>",
"    &nbsp;&mdash;&nbsp;TWA has been compared to other noninvasive predictors of sudden cardiac death and ventricular arrhythmias, such as the signal-averaged ECG (SAECG) and heart rate variability (HRV), as well as to invasive electrophysiology study (EPS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     SAECG",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have compared TWA to the SAECG [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/11,18,26\">",
"     11,18,26",
"    </a>",
"    ]. In a series of 313 patients referred for EP study, the predictive accuracy of TWA was compared to that of the SAECG and EPS [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/11\">",
"     11",
"    </a>",
"    ]. In determining the accuracy of these parameters for predicting the primary end points of ventricular tachycardia (VT), ventricular fibrillation (VF), appropriate ICD discharge, or cardiac arrest, or the secondary end point of any of these arrhythmias plus death, the following finding were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At a mean follow-up of 195+126 days, both TWA and VT induction during EPS were multivariate predictors of event-free survival.",
"     </li>",
"     <li>",
"      The relative risks (RR) for the primary end point were 10.9, 7.1, and 4.5 for TWA, EPS, and SAECG, respectively.",
"     </li>",
"     <li>",
"      The RR for the secondary end point were 13.9, 4.7 and 3.3 for TWA, EPS, and SAECG, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The implications of this report are limited by the heterogeneity of the population: 30 percent did not have structural heart disease, and 31 percent were being evaluated for supraventricular tachycardia.",
"   </p>",
"   <p>",
"    The predictive accuracy of SAECG, left ventricular ejection fraction (LVEF), and TWA during exercise were compared in a study of 102 post-MI patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/26\">",
"     26",
"    </a>",
"    ]. Positive TWA tests were present in 50 patients, a positive SAECG (defined by abnormal late potentials) in 21 patients, and LVEF &lt;40 percent in 28 patients. The following findings were noted at an average follow-up of 13 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptomatic sustained VT or VF occurred in 15 patients and was significantly more likely in those with abnormal TWA, SAECG, or LVEF.",
"     </li>",
"     <li>",
"      TWA provided a sensitivity and negative predictive value for arrhythmic events of 93 percent and 98 percent, respectively, although its positive predictive value (28 percent) was lower than for the SAECG and reduced LVEF.",
"     </li>",
"     <li>",
"      The highest positive predictive value (50 percent) was obtained when TWA and abnormal SAECG were combined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Heart rate variability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart rate variability has been shown to predict arrhythmic events in large series of post-myocardial infarction (MI) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. The ECG metric of heart rate turbulence also may be of predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/59\">",
"     59",
"    </a>",
"    ]. A study in patients with mildly reduced LVEF post-MI found that heart rate variability and heart rate turbulence predicted arrhythmic outcome, particularly when combined with TWA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link&amp;anchor=H9#H9\">",
"     \"Heart rate variability: Technical aspects\", section on 'Heart rate turbulence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     QT dispersion",
"    </span>",
"    &nbsp;&mdash;&nbsp;QT dispersion on the ECG is now largely discounted as a predictor of arrhythmic or overall mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/60\">",
"     60",
"    </a>",
"    ], as it does not accurately reflect myocardial dispersion of repolarization [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/61\">",
"     61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=see_link\">",
"     \"QT dispersion: Measurement and interpretation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=see_link\">",
"     \"QT dispersion: Clinical applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Combining TWA with other indices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to identify post-myocardial infarction (MI) patients at risk for sudden cardiac death (SCD) by combining TWA with other indices was evaluated in the REFINE study [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/28\">",
"     28",
"    </a>",
"    ]. This study included 322 individuals with modestly reduced left ventricular ejection fraction (LVEF) post-MI who were followed for a median of 47 months.",
"   </p>",
"   <p>",
"    A combination of abnormal TWA, abnormal autonomic tone (either impaired baroreflex sensitivity or reduced heart rate turbulence) and an LVEF less than 50 percent yielded a sensitivity of 37 to 55 percent and a specificity of 94 to 96 percent for predicting SCD or cardiac arrest. The optimum time to assess risk was 8 to 10 weeks postinfarction. No index predicted events when measured in the first month.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     TWA AND PHARMACOLOGIC INTERVENTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     TWA and beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential connection between TWA and beta blockers remains poorly understood. Studies have demonstrated that exercise-induced TWA is mimicked by atrial or ventricular pacing, but not by beta-adrenergic stimulation, suggesting that beta-blockade may not impact TWA [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/19,62,63\">",
"     19,62,63",
"    </a>",
"    ]. Similarly, in an observational study of 387 patients with an indication for electrophysiology study, oral beta blocker therapy was not associated with the predictive value of TWA testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conversely, the following observations support an effect of beta blockade on TWA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 54 patients with documented or suspected ventricular tachyarrhythmias,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       sotalol",
"      </a>",
"      reduced TWA amplitude [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 60 patients,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      , but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"       atropine",
"      </a>",
"      , reduced TWA amplitude and the incidence of TWA by 50 percent compared to control [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among 15 patients with ventricular tachycardia (VT) undergoing electrophysiology (EP) study, TWA was assessed during atrial pacing before and after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      administration; the rate of positive TWA was lower after propranolol administration (47 versus 73 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     TWA and procainamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most studies, antiarrhythmic drugs have been withheld prior to measuring TWA, making it difficult to determine the effect of drug therapy on TWA. This issue was studied in 24 patients undergoing EP testing [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/67\">",
"     67",
"    </a>",
"    ]. Acute administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    significantly attenuated TWA via an unclear mechanism, thereby reducing the sensitivity of TWA for predicting VT induction at EP study (87 versus 60 percent). The reduction in TWA magnitude was independent of the antiarrhythmic effects of the drug on the inducibility of VT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Identification of drugs causing proarrhythmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some early studies suggest that TWA visible on the surface electrocardiogram may reflect repolarization dispersion contributing to proarrhythmia with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , and other antiarrhythmic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/53,68-70\">",
"     53,68-70",
"    </a>",
"    ]. The potential magnitude of this effect was illustrated in a report of 100 patients receiving almokalant, a class III antiarrhythmic drug, for atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/68\">",
"     68",
"    </a>",
"    ]. Macroscopic TWA was significantly more common in patients who developed torsades de pointes than in those who did not (50 versus 4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/68\">",
"     68",
"    </a>",
"    ]. Further studies are required to confirm these findings and to determine whether they also apply to microvolt TWA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     POTENTIAL CLINICAL USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary indication for TWA approved by the United States Food and Drug Administration (FDA) is for the prediction of ventricular arrhythmias in patients at risk for sudden cardiac death (SCD). Although the FDA approval describes TWA measured during exercise, clinical studies in over 500 patients support the utility of TWA obtained during pacing at electrophysiology study to stratify risk for spontaneous ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4916038\">",
"    <span class=\"h2\">",
"     Identifying patients at low risk for VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest utility of TWA lies in its high negative predictive value and therefore in identifying low-risk individuals. Studies show that the negative predictive value of TWA for arrhythmic events occurring within one year exceeds 90 percent (range 90 to 99 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/71\">",
"     71",
"    </a>",
"    ]. Hypothetically, since TWA is a noninvasive test, it could be applied on a regular basis to determine short-term risk and the need for an ICD. The ability of TWA to identify patients who may not benefit from an ICD was recently demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/38\">",
"     38",
"    </a>",
"    ]. However, it is not known if this negative predictive value is high enough to withhold ICD implantation in patients who otherwise meet ICD implantation criteria [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TWA has been studied in the following specific populations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For risk stratification following myocardial infarction in patients with reduced LVEF. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Patients with CHD'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=see_link&amp;anchor=H16#H16\">",
"       \"Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction\", section on 'T wave (repolarization) alternans'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=see_link&amp;anchor=H5#H5\">",
"       \"Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death\", section on 'MADIT II trial'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For risk stratification among symptomatic patients with dilated cardiomyopathy. The TWA in CHF study was a prospective investigation funded by the National Institutes of Health [",
"      <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/43\">",
"       43",
"      </a>",
"      ]. It studied the prognostic utility of TWA for cardiac mortality and ventricular arrhythmias in 587 patients with ischemic and nonischemic cardiomyopathy. In accordance with other recent trials, TWA provided a negative predictive value of &gt;98 percent for this combined endpoint at one year. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Heart failure'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=see_link&amp;anchor=H20#H20\">",
"       \"Ventricular arrhythmias in heart failure and cardiomyopathy\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Macroscopic (visible) TWA is a diagnostic criterion for LQTS. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Long QT syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=see_link&amp;anchor=H13#H13\">",
"       \"Diagnosis of congenital long QT syndrome\", section on 'T wave alternans'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4916045\">",
"    <span class=\"h2\">",
"     Identifying patients at risk for impending VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the majority of literature on TWA relates to its use for long-term prognosis, the ability to identify acute changes in TWA prior to arrhythmic events could lead to its use in monitoring critically ill patients. In the PRECEDENT trial of 255 patients with symptomatic decompensated heart failure, all patients underwent 24 hour ambulatory ECG monitoring prior to randomization for therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/73\">",
"     73",
"    </a>",
"    ]. Twenty-two patients (9 percent) had nonsustained VT (range 4 to 19 beats) during the 24 hour ECG monitoring. When compared with 22 age- and sex-matched patients from the trial who did not have VT in the preceding 24 hours, patients with VT had a significant increase in TWA (28 versus 19 microvolts) between 15 and 30 minutes prior to VT which remained elevated until the arrhythmia occurred. There was also a significant increase in R-wave and T-wave heterogeneity preceding VT.",
"   </p>",
"   <p>",
"    If this finding can be replicated in a larger population and if therapy can be instituted that reduces the rate of VT, this may indicate a role for TWA in monitoring patients at high risk for developing ventricular arrhythmias.",
"   </p>",
"   <p>",
"    In another study, implanted device tracings from patients with systolic dysfunction were analyzed and found to demonstrate repolarization alternans just prior to spontaneous ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/74\">",
"     74",
"    </a>",
"    ]. This further strengthens the mechanistic link between repolarization alternans and potentially lethal arrhythmias, and it opens the door for applications to predict imminent VT or VF. Future studies are required to determine whether strategies can then be effectively applied to prevent the initiation of such arrhythmias.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Major society guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major limitation to implementation of TWA protocols is that specific guidance is not available on how to use TWA in clinical practice. In addition, the optimum measurement conditions and criteria for detecting TWA remain controversial. These issues are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9800?source=see_link\">",
"     \"T wave (repolarization) alternans: Technical aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We agree with the 2008 American Heart",
"    <span class=\"nowrap\">",
"     Association/American",
"    </span>",
"    College of",
"    <span class=\"nowrap\">",
"     Cardiology/Heart",
"    </span>",
"    Rhythm Society",
"    <span class=\"nowrap\">",
"     (AHA/ACC/HRS)",
"    </span>",
"    scientific statement on noninvasive risk stratification, which concluded that a moderate amount of data suggest that TWA may be useful for risk stratification for SCD, but that further information will be needed to determine the clinical applicability of this test [",
"    <a class=\"abstract\" href=\"UTD.htm?5/48/5898/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3515283\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T-wave alternans (TWA) refers to beat-to-beat variability in the timing or shape of T-waves on the surface electrocardiogram (ECG), which may be macroscopic (visibly apparent on the ECG) or microscopic (requiring computerized analysis). There are two predominant methods for determining TWA, the spectral approach and the newer modified moving average approach, with most data having been accrued using the spectral approach. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9800?source=see_link\">",
"       \"T wave (repolarization) alternans: Technical aspects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      TWA reflects temporal heterogeneity or dispersion in ventricular repolarization, which is an important mechanism underlying reentrant arrhythmias. Thus, TWA is a noninvasive method for assessing risk for sudden cardiac arrest using the surface ECG. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk stratification for SCD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients at high risk for arrhythmic events, TWA has a high negative predictive value for clinical sudden cardiac arrest. Patients without evidence of TWA may derive less benefit from an ICD. (See",
"      <a class=\"local\" href=\"#H3515198\">",
"       'Patients at high risk for ventricular arrhythmias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some of the earliest reports of macroscopic TWA were in patients with the long QT syndrome (LQTS), and macroscopic TWA remains a part of the LQTS score that is most often used for diagnosis. Macroscopic TWA is, however, much less commonly seen than microvolt TWA in LQTS. The predictive value of microvolt TWA remains to be determined in the various genotypes of LQTS. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Long QT syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The greatest potential for routine clinical use of TWA appears to be for prediction of ventricular arrhythmias following myocardial infarction in patients with reduced LVEF and in symptomatic patients with dilated cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Potential clinical uses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/1\">",
"      Smith JM, Clancy EA, Valeri CR, et al. Electrical alternans and cardiac electrical instability. Circulation 1988; 77:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/2\">",
"      Rosenbaum DS, Jackson LE, Smith JM, et al. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994; 330:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/3\">",
"      Kuo CS, Munakata K, Reddy CP, Surawicz B. Characteristics and possible mechanism of ventricular arrhythmia dependent on the dispersion of action potential durations. Circulation 1983; 67:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/4\">",
"      Narayan SM. T-wave alternans and the susceptibility to ventricular arrhythmias. J Am Coll Cardiol 2006; 47:269.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/510kClearances/ucm093462.htm (Accessed on December 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/6\">",
"      Myles RC, Jackson CE, Tsorlalis I, et al. Is microvolt T-wave alternans the answer to risk stratification in heart failure? Circulation 2007; 116:2984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/7\">",
"      Buxton AE, Lee KL, DiCarlo L, et al. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 2000; 342:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/8\">",
"      Moss AJ, Daubert J, Zareba W. MADIT-II: clinical implications. Card Electrophysiol Rev 2002; 6:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/9\">",
"      Gehi AK, Stein RH, Metz LD, Gomes JA. Microvolt T-wave alternans for the risk stratification of ventricular tachyarrhythmic events: a meta-analysis. J Am Coll Cardiol 2005; 46:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/10\">",
"      Hohnloser SH, Klingenheben T, Li YG, et al. T wave alternans as a predictor of recurrent ventricular tachyarrhythmias in ICD recipients: prospective comparison with conventional risk markers. J Cardiovasc Electrophysiol 1998; 9:1258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/11\">",
"      Gold MR, Bloomfield DM, Anderson KP, et al. A comparison of T-wave alternans, signal averaged electrocardiography and programmed ventricular stimulation for arrhythmia risk stratification. J Am Coll Cardiol 2000; 36:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/12\">",
"      Hohnloser SH, Klingenheben T, Bloomfield D, et al. Usefulness of microvolt T-wave alternans for prediction of ventricular tachyarrhythmic events in patients with dilated cardiomyopathy: results from a prospective observational study. J Am Coll Cardiol 2003; 41:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/13\">",
"      Kaufman ES, Bloomfield DM, Steinman RC, et al. \"Indeterminate\" microvolt T-wave alternans tests predict high risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 2006; 48:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/14\">",
"      Ikeda T, Saito H, Tanno K, et al. T-wave alternans as a predictor for sudden cardiac death after myocardial infarction. Am J Cardiol 2002; 89:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/15\">",
"      Chow T, Kereiakes DJ, Bartone C, et al. Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy. J Am Coll Cardiol 2006; 47:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/16\">",
"      Chan PS, Bartone C, Booth T, et al. Prognostic implication of redefining indeterminate microvolt T-wave alternans studies as abnormal or normal. Am Heart J 2007; 153:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/17\">",
"      Buxton AE, Hafley GE, Lehmann MH, et al. Prediction of sustained ventricular tachycardia inducible by programmed stimulation in patients with coronary artery disease. Utility of clinical variables. Circulation 1999; 99:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/18\">",
"      Estes NA 3rd, Michaud G, Zipes DP, et al. Electrical alternans during rest and exercise as predictors of vulnerability to ventricular arrhythmias. Am J Cardiol 1997; 80:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/19\">",
"      Narayan SM, Smith JM. Exploiting rate-related hysteresis in repolarization alternans to improve risk stratification for ventricular tachycardia. J Am Coll Cardiol 2000; 35:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/20\">",
"      Narayan SM, Smith JM. Differing rate dependence and temporal distribution of repolarization alternans in patients with and without ventricular tachycardia. J Cardiovasc Electrophysiol 1999; 10:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/21\">",
"      Nearing BD, Verrier RL. Modified moving average analysis of T-wave alternans to predict ventricular fibrillation with high accuracy. J Appl Physiol 2002; 92:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/22\">",
"      Leino J, Minkkinen M, Nieminen T, et al. Combined assessment of heart rate recovery and T-wave alternans during routine exercise testing improves prediction of total and cardiovascular mortality: the Finnish Cardiovascular Study. Heart Rhythm 2009; 6:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/23\">",
"      Ikeda T, Yoshino H, Sugi K, et al. Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction: results of a collaborative cohort study. J Am Coll Cardiol 2006; 48:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/24\">",
"      Leino J, Verrier RL, Minkkinen M, et al. Importance of regional specificity of T-wave alternans in assessing risk for cardiovascular mortality and sudden cardiac death during routine exercise testing. Heart Rhythm 2011; 8:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/25\">",
"      Rashba EJ, Osman AF, MacMurdy K, et al. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol 2002; 13:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/26\">",
"      Ikeda T, Sakata T, Takami M, et al. Combined assessment of T-wave alternans and late potentials used to predict arrhythmic events after myocardial infarction. A prospective study. J Am Coll Cardiol 2000; 35:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/27\">",
"      Tapanainen JM, Still AM, Airaksinen KE, Huikuri HV. Prognostic significance of risk stratifiers of mortality, including T wave alternans, after acute myocardial infarction: results of a prospective follow-up study. J Cardiovasc Electrophysiol 2001; 12:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/28\">",
"      Exner DV, Kavanagh KM, Slawnych MP, et al. Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol 2007; 50:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/29\">",
"      Junttila MJ, Barthel P, Myerburg RJ, et al. Sudden cardiac death after myocardial infarction in patients with type 2 diabetes. Heart Rhythm 2010; 7:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/30\">",
"      Martin DT, Shoraki A, Nesto RW, Rutter MK. Influence of diabetes and/or myocardial infarction on prevalence of abnormal T-wave alternans. Ann Noninvasive Electrocardiol 2009; 14:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/31\">",
"      Molon G, Costa A, Bertolini L, et al. Relationship between abnormal microvolt T-wave alternans and poor glycemic control in type 2 diabetic patients. Pacing Clin Electrophysiol 2007; 30:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/32\">",
"      Costantini O, Hohnloser SH, Kirk MM, et al. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention. J Am Coll Cardiol 2009; 53:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/33\">",
"      K&oslash;ber L, Torp-Pedersen C, Pedersen OD, et al. Importance of congestive heart failure and interaction of congestive heart failure and left ventricular systolic function on prognosis in patients with acute myocardial infarction. Am J Cardiol 1996; 78:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/34\">",
"      Klingenheben T, Zabel M, D'Agostino RB, et al. Predictive value of T-wave alternans for arrhythmic events in patients with congestive heart failure. Lancet 2000; 356:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/35\">",
"      Salerno-Uriarte JA, De Ferrari GM, Klersy C, et al. Prognostic value of T-wave alternans in patients with heart failure due to nonischemic cardiomyopathy: results of the ALPHA Study. J Am Coll Cardiol 2007; 50:1896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/36\">",
"      Morin DP, Zacks ES, Mauer AC, et al. Effect of bundle branch block on microvolt T-wave alternans and electrophysiologic testing in patients with ischemic cardiomyopathy. Heart Rhythm 2007; 4:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/37\">",
"      Narayan SM, Smith JM, Schechtman KB, et al. T-wave alternans phase following ventricular extrasystoles predicts arrhythmia-free survival. Heart Rhythm 2005; 2:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/38\">",
"      Chow T, Kereiakes DJ, Bartone C, et al. Microvolt T-wave alternans identifies patients with ischemic cardiomyopathy who benefit from implantable cardioverter-defibrillator therapy. J Am Coll Cardiol 2007; 49:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/39\">",
"      Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/40\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/41\">",
"      Hohnloser SH, Ikeda T, Bloomfield DM, et al. T-wave alternans negative coronary patients with low ejection and benefit from defibrillator implantation. Lancet 2003; 362:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/42\">",
"      Bloomfield DM, Steinman RC, Namerow PB, et al. Microvolt T-wave alternans distinguishes between patients likely and patients not likely to benefit from implanted cardiac defibrillator therapy: a solution to the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II conundrum. Circulation 2004; 110:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/43\">",
"      Bloomfield DM, Bigger JT, Steinman RC, et al. Microvolt T-wave alternans and the risk of death or sustained ventricular arrhythmias in patients with left ventricular dysfunction. J Am Coll Cardiol 2006; 47:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/44\">",
"      Chan PS, Stein K, Chow T, et al. Cost-effectiveness of a microvolt T-wave alternans screening strategy for implantable cardioverter-defibrillator placement in the MADIT-II-eligible population. J Am Coll Cardiol 2006; 48:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/45\">",
"      Chow T, Kereiakes DJ, Onufer J, et al. Does microvolt T-wave alternans testing predict ventricular tachyarrhythmias in patients with ischemic cardiomyopathy and prophylactic defibrillators? The MASTER (Microvolt T Wave Alternans Testing for Risk Stratification of Post-Myocardial Infarction Patients) trial. J Am Coll Cardiol 2008; 52:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/46\">",
"      Gold MR, Ip JH, Costantini O, et al. Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation 2008; 118:2022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/47\">",
"      Hohnloser SH, Ikeda T, Cohen RJ. Evidence regarding clinical use of microvolt T-wave alternans. Heart Rhythm 2009; 6:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/48\">",
"      Kitamura H, Ohnishi Y, Okajima K, et al. Onset heart rate of microvolt-level T-wave alternans provides clinical and prognostic value in nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2002; 39:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/49\">",
"      Grimm W, Christ M, Bach J, et al. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003; 108:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/50\">",
"      Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome. An update. Circulation 1993; 88:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/51\">",
"      Zareba W, Moss AJ, le Cessie S, Hall WJ. T wave alternans in idiopathic long QT syndrome. J Am Coll Cardiol 1994; 23:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/52\">",
"      Burattini L, Zareba W, Rashba EJ, et al. ECG features of microvolt T-wave alternans in coronary artery disease and long QT syndrome patients. J Electrocardiol 1998; 31 Suppl:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/53\">",
"      Habbab MA, el-Sherif N. TU alternans, long QTU, and torsade de pointes: clinical and experimental observations. Pacing Clin Electrophysiol 1992; 15:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/54\">",
"      Chinushi M, Restivo M, Caref EB, El-Sherif N. Electrophysiological basis of arrhythmogenicity of QT/T alternans in the long-QT syndrome: tridimensional analysis of the kinetics of cardiac repolarization. Circ Res 1998; 83:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/55\">",
"      Cruz Filho FE, Maia IG, Fagundes ML, et al. Electrical behavior of T-wave polarity alternans in patients with congenital long QT syndrome. J Am Coll Cardiol 2000; 36:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/56\">",
"      Momiyama Y, Hartikainen J, Nagayoshi H, et al. Exercise-induced T-wave alternans as a marker of high risk in patients with hypertrophic cardiomyopathy. Jpn Circ J 1997; 61:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/57\">",
"      Kleiger RE, Miller JP, Bigger JT Jr, Moss AJ. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. Am J Cardiol 1987; 59:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/58\">",
"      Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. J Am Coll Cardiol 1991; 18:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/59\">",
"      Schmidt G, Malik M, Barthel P, et al. Heart-rate turbulence after ventricular premature beats as a predictor of mortality after acute myocardial infarction. Lancet 1999; 353:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/60\">",
"      Zabel M, Klingenheben T, Franz MR, Hohnloser SH. Assessment of QT dispersion for prediction of mortality or arrhythmic events after myocardial infarction: results of a prospective, long-term follow-up study. Circulation 1998; 97:2543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/61\">",
"      Burnes JE, Ghanem RN, Waldo AL, Rudy Y. Imaging dispersion of myocardial repolarization, I: comparison of body-surface and epicardial measures. Circulation 2001; 104:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/62\">",
"      Klingenheben T, Gr&ouml;nefeld G, Li YG, Hohnloser SH. Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. J Am Coll Cardiol 2001; 38:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/63\">",
"      Kaufman ES, Mackall JA, Julka B, et al. Influence of heart rate and sympathetic stimulation on arrhythmogenic T wave alternans. Am J Physiol Heart Circ Physiol 2000; 279:H1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/64\">",
"      Zacks ES, Morin DP, Ageno S, et al. Effect of oral beta-blocker therapy on microvolt T-wave alternans and electrophysiology testing in patients with ischemic cardiomyopathy. Am Heart J 2007; 153:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/65\">",
"      Rashba EJ, Cooklin M, MacMurdy K, et al. Effects of selective autonomic blockade on T-wave alternans in humans. Circulation 2002; 105:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/66\">",
"      Komiya N, Seto S, Nakao K, Yano K. The influence of beta-adrenergic agonists and antagonists on T-wave alternans in patients with and without ventricular tachyarrhythmia. Pacing Clin Electrophysiol 2005; 28:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/67\">",
"      Kavesh NG, Shorofsky SR, Sarang SE, Gold MR. Effect of heart rate on T wave alternans. J Cardiovasc Electrophysiol 1998; 9:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/68\">",
"      Houltz B, Darp&ouml; B, Edvardsson N, et al. Electrocardiographic and clinical predictors of torsades de pointes induced by almokalant infusion in patients with chronic atrial fibrillation or flutter: a prospective study. Pacing Clin Electrophysiol 1998; 21:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/69\">",
"      Surawicz B, Fisch C. Cardiac alternans: diverse mechanisms and clinical manifestations. J Am Coll Cardiol 1992; 20:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/70\">",
"      Bardaj&iacute; A, Vidal F, Richart C. T wave alternans associated with amiodarone. J Electrocardiol 1993; 26:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/71\">",
"      Narayan SM. Is T-wave alternans as good or better than programmed ventricular stimulation? Heart Rhythm 2007; 4:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/72\">",
"      Cantillon DJ, Stein KM, Markowitz SM, et al. Predictive value of microvolt T-wave alternans in patients with left ventricular dysfunction. J Am Coll Cardiol 2007; 50:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/73\">",
"      Nearing BD, Wellenius GA, Mittleman MA, et al. Crescendo in depolarization and repolarization heterogeneity heralds development of ventricular tachycardia in hospitalized patients with decompensated heart failure. Circ Arrhythm Electrophysiol 2012; 5:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/74\">",
"      Swerdlow C, Chow T, Das M, et al. Intracardiac electrogram T-wave alternans/variability increases before spontaneous ventricular tachyarrhythmias in implantable cardioverter-defibrillator patients: a prospective, multi-center study. Circulation 2011; 123:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/48/5898/abstract/75\">",
"      Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation 2008; 118:1497.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2109 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-FFFC22E1CE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5898=[""].join("\n");
var outline_f5_48_5898=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3515283\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK STRATIFICATION FOR SCD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indeterminate results",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Predicting inducible VT/VF at electrophysiology study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Predicting clinical arrhythmic events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Unselected populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3515198\">",
"      - Patients at high risk for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Patients with CHD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H3515216\">",
"      Diabetic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LV systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Widened QRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Identifying a low-risk subgroup from identified high-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other patient populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Nonischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Comparison to other predictors of arrhythmic events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - SAECG",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Heart rate variability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - QT dispersion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Combining TWA with other indices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      TWA AND PHARMACOLOGIC INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      TWA and beta blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TWA and procainamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Identification of drugs causing proarrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      POTENTIAL CLINICAL USES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4916038\">",
"      Identifying patients at low risk for VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4916045\">",
"      Identifying patients at risk for impending VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Major society guidelines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3515283\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/2109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2109|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/26/22957\" title=\"figure 1\">",
"      TW alternans and arrhythmic events post-MI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/62/21486\" title=\"figure 2\">",
"      TW alternans and late potentials predict arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/2109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/11/4282?source=related_link\">",
"      Conduction abnormalities after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/6/33897?source=related_link\">",
"      Diagnosis of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29129?source=related_link\">",
"      Exercise ECG testing to determine prognosis of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19657?source=related_link\">",
"      Implantable cardioverter-defibrillators: Clinical trials of primary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/24/20874?source=related_link\">",
"      Incidence of and risk stratification for sudden cardiac death after acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9591?source=related_link\">",
"      Pathophysiology of the long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26682?source=related_link\">",
"      Prognosis and management of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/33/10778?source=related_link\">",
"      QT dispersion: Clinical applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/51/26425?source=related_link\">",
"      QT dispersion: Measurement and interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/62/15338?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9800?source=related_link\">",
"      T wave (repolarization) alternans: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/47/21241?source=related_link\">",
"      Ventricular arrhythmias in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_48_5899="HIPEC parameters";
var content_f5_48_5899=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76769&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Typical HIPEC parameters used at various centers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Duration:",
"      </td>",
"      <td>",
"       90 to 120 mins",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Target temperature:",
"      </td>",
"      <td>",
"       40 to 42.5 degrees Celsius",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Perfusate volume:",
"      </td>",
"      <td>",
"       4 to 6 liters",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Flow rate:",
"      </td>",
"      <td>",
"       1 to 1.5 liters/min",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" rowspan=\"3\">",
"       Agents*:",
"      </td>",
"      <td>",
"       <p>",
"        Mitomycin C",
"       </p>",
"       <p>",
"        Doxorubicin",
"       </p>",
"       <p>",
"        Cisplatin",
"       </p>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HIPEC: hyperthermic intraperitoneal chemotherapy.",
"     <br>",
"      * Alone or in combination.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5899=[""].join("\n");
var outline_f5_48_5899=null;
var title_f5_48_5900="Contraindications TTO2";
var content_f5_48_5900=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73278&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications to transtracheal oxygen",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Relative contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PaO",
"        <sub>",
"         2",
"        </sub>",
"        &lt;55 mgHg at oxygen flow rate of 8 L/min or greater",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PaCO",
"        <sub>",
"         2",
"        </sub>",
"        &gt;50 mmHg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FEV1 &lt;500 mL or less than 70 percent of baseline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anatomic abnormality that makes insertion difficult (severe obesity, deviated trachea, previous tracheostomy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulopathy, or medications that increase bleeding risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risk of delayed healing (diabetes mellitus, glucocorticoid dependence, connective tissue disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled bronchial hyperreactivity (eg, greater than 12 percent increase in post-bronchodilator spirometry)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor mechanical reserve, weak cough",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Copious or viscous sputum production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mild to moderate anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Absolute contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inability to practice self-care, including periodic stripping of catheter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncompensated (acute) respiratory acidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe coagulopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pleura herniated over puncture site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Conditions that predispose to upper airway obstruction (subglottic stenosis, bilateral vocal cord paralysis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor adherence to medical regimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medically unstable",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5900=[""].join("\n");
var outline_f5_48_5900=null;
var title_f5_48_5901="Diagnostic tests for adenovirus";
var content_f5_48_5901=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59727&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic tests for adenovirus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnostic test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Appropriate samples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Viral culture",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Nasopharyngeal swabs or aspirates",
"         </li>",
"         <li>",
"          Throat swabs or washes",
"         </li>",
"         <li>",
"          Sputum, tracheal aspirates, or BAL fluid",
"         </li>",
"         <li>",
"          Conjunctival swabs or scrapings",
"         </li>",
"         <li>",
"          Stool or rectal swabs",
"         </li>",
"         <li>",
"          Urine",
"         </li>",
"         <li>",
"          Cerebrospinal fluid",
"         </li>",
"         <li>",
"          Tissue samples",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Samples should be placed in viral transport medium and transported on ice.",
"        </p>",
"        <p>",
"         Results available in 2 to 7 days for most serotypes, but up to 28 days for subgroup D serotypes (which cause epidemic keratoconjunctivitis).",
"        </p>",
"        <p>",
"         All adenovirus serotypes except 40 and 41 cause characteristic CPE in human epithelial cell lines and human embryonic kidney cells.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Viral antigen assays",
"        </strong>",
"        (eg, adenovirus specific enzyme-linked immunosorbent assay or immunofluorescence assay)",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Nasopharyngeal swabs or aspirates",
"         </li>",
"         <li>",
"          Throat swabs or washes",
"         </li>",
"         <li>",
"          Tracheal aspirate or BAL material",
"         </li>",
"         <li>",
"          Conjunctival swabs or scrapings",
"         </li>",
"         <li>",
"          Stool or rectal swabs",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Results available in less than 30 minutes.",
"        </p>",
"        <p>",
"         Specific, but less sensitive than viral culture for respiratory secretions.",
"        </p>",
"        <p>",
"         Test of choice for adenovirus serotypes 40 and 41 (which cause infantile gastroenteritis); adjunct to viral culture for epidemic keratoconjunctivitis (more rapid results for subgroup D serotypes).",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Polymerase chain reaction",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Nasopharyngeal swabs or aspirates",
"         </li>",
"         <li>",
"          Throat swabs or washes",
"         </li>",
"         <li>",
"          Sputum, tracheal aspirates, or BAL fluid",
"         </li>",
"         <li>",
"          Blood",
"         </li>",
"         <li>",
"          Urine",
"         </li>",
"         <li>",
"          Stool",
"         </li>",
"         <li>",
"          Cerebrospinal fluid",
"         </li>",
"         <li>",
"          Biopsy specimens",
"         </li>",
"         <li>",
"          Fixed tissue",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Rapid diagnosis of adenovirus infection in immunocompromised patients and other hospitalized patients.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Histopathologic studies",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Tissue",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         Adenoviruses cause characteristic intranuclear inclusions; should be performed in conjunction with viral culture because histopathologic changes may be nonspecific, especially during the early stage of adenovirus infection.",
"        </p>",
"        <p>",
"         Immunohistochemistry, in situ hybridization, or electron microscopy can be used to definitively identify adenoviruses in tissue sections.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Serology",
"        </strong>",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          Blood",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        Adenovirus-specific IgM antibody suggests acute infection. Fourfold or greater rise in adenovirus specific IgG antibodies confirms recent infection.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BAL: bronchoalveolar lavage; CPE: cytopathic effect.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5901=[""].join("\n");
var outline_f5_48_5901=null;
var title_f5_48_5902="Contents: General Surgery";
var content_f5_48_5902=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      General Surgery",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			General Surgery",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?40/52/41805\">",
"         Bariatric metabolic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/39/33407\">",
"         Breast surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?35/20/36174\">",
"         Burn surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/38/14944\">",
"         Colorectal surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/44/41666\">",
"         Endocrine surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/0/37902\">",
"         Esophageal surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?38/38/39533\">",
"         General surgery calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/9/17567\">",
"         General surgical principles",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?25/58/26543\">",
"         Gynecologic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/29/23007\">",
"         Head and neck surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?10/18/10528\">",
"         Hepatobiliary surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?4/8/4238\">",
"         Hernia surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?29/1/29725\">",
"         Minimally invasive surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/11/22718\">",
"         Pancreatic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?5/42/5807\">",
"         Plastic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?13/15/13566\">",
"         Principles of anesthesia and analgesia",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?23/37/24158\">",
"         Skin and soft tissue surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?28/6/28782\">",
"         Thoracic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?4/42/4782\">",
"         Trauma surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/20/38210\">",
"         Upper GI surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?31/54/32615\">",
"         Urologic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/38/41570\">",
"         Vascular surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/62/19431\">",
"         What's new in general surgery",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-96DEDC86B4-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f5_48_5902=[""].join("\n");
var outline_f5_48_5902=null;
var title_f5_48_5903="Tonsil forceps";
var content_f5_48_5903=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71094&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tonsil forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 231px; height: 372px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemostatic tonsil forceps have a small tooth grip.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_48_5903=[""].join("\n");
var outline_f5_48_5903=null;
